var title_f6_0_6144="Pneumopericardium in a neonate";
var content_f6_0_6144=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pneumopericardium in a neonate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 276px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEUAXADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5Vx60Dk1YMWRSCPn39DQBBiip/KJIHBzSGLv2oAgoqRo8UGM0AWdPQbwxFdLbiF8fKR3wRmuXt4SWBBPWtKCN1YMXIPrmgDpYbSGTBKKRnqOOKv2+l2NwcyooP+yOawLOSaI4BHXGCK6XSr1GKCVNhwPmWgC9D4RLIGtJFbIyMnt9aUaLc2rbZYGU9d2OMV0+gFPNiaKVXXdnA7/5/pXqmkWlnfWqmRV3Ac5HNAHitlbsijIOOa7fwtq0lqyRPIfLPIJPSuwvvCenyHIjRW65AxWTJ4TaP/VMSD0yM0AdZZX4dU+bIYZ69RWpHOGAJPHTnvXHabp95bPsb5krpbaCRo/vjPGaANGKcq2c9ecelaUMpYAjpWSkJABLHbn0qzbnyxhvu+vpQBsRORjtx1FXopXAGOD061mROGUYH61bg5I2/hmgDTium6MScd6fI/mKQT+fas8hljB7HqQO9M+0MnD5PtQBdWMsTtY8etTFH8kYYZHrVWC5Q9etTLcIxZePYUAOmUuiMT8w4x601VLx4dssDQsw8txkn171FFODuUOMY70AW1ZUHy8A1UvZvlkKMFV1KyE9BxgN/IH2+lMWXLZIpxOAwPOev0oAhuLrzYlYfKGGcEdPUf0qmlypLbWD7WKHB6MOx9D0496lk2RAqmRuO498dPX6VBJchN3IHrQBJ5jkDAfnjFKIZG4Y7fb0qpJqkcQxkAe/asu88Twwg4kQkf56UAdAkMEOd5AGTyeeOtUNR1CFIDtfaCK4bUvFrStiORv+ArXNXOuuBJjzHkc/x/zoA0/E2oRQgymTKlvlUd6831PUpbpioLRoT90d/rV69nkuJDJOx28gDsPwrMaD5snGevPWgDOliJyGHB4Oec1A0HJXOfw5Fapj4AJ5PcGoZYgFYr+BoAxbmJVO0464z61U8h3OAv0962xAZnUAZOOh9K0Es0RAMZbHWgDjZrZ4zkqQOxxTDNMi4jmkUezEZrqryCMKxwQM459K56eJRIxQHn+VADfDF9JZ63BOzMSjgkk19G215/a1nBLFIhUL6/rXzRCu2fjp14ro9L1u+05NttMyqOxJwPpQB9LaA1pZXEXnNGZC+QCe59a6bxHKk1nGqlfrjkV8pWeuX1zqNo1zcOyCUHbkjvX0Xpt+L/T4njXcoAw2773XPHt7+tAHwc8YHJ4qPYQ2P0rXu7YxOyAcAelUWjBxjPTPOOKAKypn8efpTvKyeB+lWQuRz+lSxIA+SBQBBHp5kXJ/LHNJPYGNc8kd+K3LZ4yADwcDrV37KGB4yT+lAHLWsI5z7e9alvCGwv61cm0sx/vIuQeTjtUtvEMH1+nGKAFggwMY96vRQHjcOc+lLDHxnbWjBEMgduhxzQBPp2+B1ZCyfQda6/TdfuoYURi2R0ZDz+NczBGePYYzitO3ixuC49ucZoA7Wz8V3JAVnBGOMrWrF4lR+H8zce46VxFrGSOABg+vWtOBCcA4HYYFAHXxavDL0mIbrjFaNtqI5KyD1+tcdAoU49+o9KuxqVJ29PY0AdtbairNhwemfr7VeS4RgCemehriba8lUjLZGMe5rWtrwPGPmOeTz3oA6OK7EbYHC5PatKDUFPCspPSuWgZ2ChT34BqWFysgHU46+tAHbxXaunP06U2QowJ9RXPxXEgBIJ9x61HJqzRTKOwz8uOvTn8OfzoA3WUZyo57Yz/n0psblZF+uPXimQXiPCCD2zmj7UOQUBx3oAuJ8twc8hhjpSxALPtPSqsl0THG6gfWsa81YpcuqkE7sewHv/hQB1ReONtzEcdKrT3sRzk8dax5rozKGVmyeoBqhMzR/MWx6ZOcUAaV3qAV8IqsfUmsK+1JyfkwSeCBziqd9cSSthsjHas+Xkks35NigCK/u5WbBkb3XpWPcEsMYI9eOa05I+DVWVF2khuv6UAY8mQS2Mk561SuBnJHQDPAzmta4jABPbJPFVXiJccc9hQBjvFuBIXJ6ciq7RcEBT6ZFa0qBR0OCOQT09qrFPkOSMH2NAGa0eDwR6HiltbI3MhROcdhU7xErjvxxXS+FtMO7zGHLdOKAKth4YAgYMPnbAP0qjq9ithGzOAI19+Sewr0+2tSFw/fLemPb/69cT4zjW4d4wAEjGM+vvQB5pdyPM+TlU9M1nSx8DA9M1qyqAeR7enFU5ECrnpgetAGTKoWfjGOuanUcdcj0pbpMYJ7DApo5GT0oAuae+26Q474x6GvQvDvie60rasTq8fXDHpXmoYodwGCOaux3zbfmfn0A/SgDmdVtg8Jb+JefwzWG6DHH5V0WoH9xITjHfNYgVc/TmgCAR9ARj6VIqH+HAHSnlee/HanpHllXOTQAxY+AcYHsK0tPumQ7JfunofSoEUjDAMc+/rVu0tg0o7UAddpekGUZCgqRkDHFXbvwyMkquPfFafgpNym3mPGPlPce1d0umRTN5cmAw7etAHi81oYJnjwOPWrUEILDj0xnvXceIfDhWYsF5xwccGsE6bJE3II9BigCrbwjB24zj0rRt4RjHY9/wCtPjswrIAwbKhuOx9K0LSEgDPr+lAC20YXKgZ+taEUPAwB9B1pbS1eVgqKWY8ACun07w7KUDTkgfzoAwYUAPyqSRx0zWjDYyuM42r0ya1L1rHSEy7KhxnGeTWLJ4lW5yLYpGOx6mgDbFhHGPmIAA+8eKVUtwRh1zk1zxuZJXzJIz5PGT1qzE+0/K4wMdBwD2oA6m3lijKgnIJAzjv/AJGKsRTx+cQzcj26CuejPmxFX5DcY6Y/+vVmBpBNtk2liPlf+9+HY0AdlAY9oG5WAHB61RvLRWYkrn09ahsXYRYyQDg8dquedzzyD/nNAFVJJYFwDkYPbpVZtSlRDngHt61pyQeauQ2AfzrLnsXkyfMBB4+lAFiw1JriN0KncvIxVFbWae7ZmXq1XNOtTbzZ8wnIwa0YkCyEnGc9hQBNbWxWI7z2qndQgr97Jq3NO0annt1FZFxds7jD857dKAGXFplSAvPvWe9kSATwcYq7NdEoQPmJGOlUprlwfvBcHpQBA9hI+eh75NUZ7eROqnjgcc1oDU3hbD4ZQM8jFXLa8trgsrqQevqKAOTmiwH69Pw6VXaMKwwOQOprt7nSI7iItFwx9P8APWsO+0t7dhuGUPpQBzEqEnbuOFPHPb0qo8OeSCVx379a3JYMfKCST2A5qe20oth5wEUHIGeaAMWwsPNlyBgE9COld/oNlFZxgsQzEZGe1YjXFtZKRld/qfWmW+qlrhVThTyoIzz/AJzQB2SyboJWwCOSuOtcPrVqGVj3roLS+3WxLMAVZg248cf0qhdkTRb1yM/MAev/ANbigDyDVYPLunXkrVe3sHnUucqvQYHU+n0rpNX095dQ3bflPWoWCxgKp+UDntQByt9ZPAM5ypqgo2rx2OOfSt3W5lLMgUbs1gOxWQ4OSaAEYqFPGT09cVWmfauATk1JKwOSCBnjIqlcSBFbkYNAFbUpshU69z2qoFBGCMcHjJ5qEOWJYk59TU0Z5GQATQA/YD1GeMH0qWJB1HJHbvSKADjIHPFSJlmbb2PJ/pQBJGoOSP0rU0eHzLlcDPeqMa475/rW7oEebjJGaAO48OweTPE/TB4J7/Su5uJ1j8mU89BXL6PCm3BIA9RW4ksYiWPOSf0FADbnUUmuMMTtXIAPeohFaXDdlI4GOfwrOvFEchBz9CeMUm0DkZJ659RQBel0qPOY2I9Qen502PT3UqWAA6Co4i+VAJ9ua0VMoDE5P06UAdP4Z0+3t4POmKk+56e5NReKvFlrY2zwWZWSVR94Hj8K46+u7iQFYEO3qMtWQ2nyz5aWQ7x7Z6UAZes6rcXcrPO5znOOvNZ9tdyeehiPQ9O9b0+m2sSO8798YJxuqLT7zT7eXEMas2ONg49+tAHR6ZDNdxxts8v/AHvWtqGxYvktntisbT9aJTEcWzPTdWkmp3DvwwwegwMe9AGpb2OXKnjjPFXo7JZFCtIAeGXjow5B/Pt3FZ1lfncN44BPb9avx3gZztUYPH4UAbdjB5kCOSFLKDjPAyOlRTwtHIBzgfrTNIvGe3jDY3oAhHoRx/SrdywYEsefX1oAekqFACR+JqDdHz8wPtgVnXBJU7gSPbvWeNxbAz1x1oA6PcAp5BPrTbeZzIcD6VTso9ygks31PJrXtowAC204oAjuY3MZ69PSseaBg2ccnuK3ry4UA53Z6BRxWe0ysuA3H1oAy542QHK4OeD3NZOoXPkozn5tozx3ro9RkjWIeZjb9eori/EGp2iKPNLFWbnaM0Ac/d6vPJL94KucAZrQ0jVHDhJemepPWq2/TbpRvkQcYAYY/wAmkGnRkkWsxIJ4wQR06ZoA9K0S7SZAY3HQ8Gull05JYAwYSbhyuMflXlFlFcWzAxMSqjgiuz0bW7sIqSKHOcAE8/nQBlaqhtbto7eFQeuWGdp/zise6knbAeQljyMcAV0GqJM0slw/zFzzjsawLkE7io6jpQBlTRmOSSSWQksAFTaMKRnJz3zkcHpj3qzYO7ODyAB26moJEyRuyR3B4pUkK/L0UdfpQBpzSEM8bZcSlc+gUgBifYbT+YqzNG0rgw4AY5fP0qlakyAIvIIrUAWOOPqCRzz0OKAOa1sooCbOByCeuK5XVbpYYj8xLdVxx+FbniW7WJ3yST0x0rhb2WSSVmY5HTBoApXTFizOcnPOaz7kkMDnk1ckI45OCck1Tlha5OxSSTjkHGO9AFSQ5PAyaueHPDepeJ9Yh07S7cy3D8n+6i92Y9gPWuu8DeCrzxDdmK2URwRjdcXUvEcK+rH8+K1/HXjHTfDmh3XhvwL8qSLtvNV6SXJ7hT2WgDwqF+OD7j3q1G2QcgEVRgYHk4/D+VaEJBA57DvQBOgO7BGccE1ZgQo2znBBIP8Aj6nmoEBCgjkdatwgMVLE8dKAJ41zjtW1pJa2nCsOSAcZ4GRxmsuBAQoGMDue9XoQd+ed2c89aAPRdInMgjOckfpWk2RIjnt0AFYXh6TMKYPIHStlmypwRQAy4xIMN69fQ0/TLG4urqOKBA5JGCT+uarux5DEZ/Kul8H6lbWDO10Qrfw460AdFp/hYWUXnXkoMvYA8LWRrF3aQAxIFC+54qDxR4s3r5dtKoB96841HVJJpWbzuD2zQB0d5rFvFuVSDnjp1rGn1Z2kZV+VR39q58y7mIb/AL6zmjzhtOT83QHPWgCTVZGZs+Yzbhjr2o0u2C4Cggnrk1SdvtF0kYB3HgkDgV1OnabNlSsXsrHqPSgC7YIFKjGT39a14VPmZJHpmn2mlkFNxG4jrjrWstpHFxwvABJPUe9AFe2Vc47HjIrRt1LKN3D+gOcf4061gTcR0GOQOtXLaCISlCGJXBJKnH0zQBaswIMyvhYiP3h7Kw6MfbHBPsKtyyhnOT26H1qe3RFjG44B4571k3cf2e5JPFuP/If0/wBn+X06AGsvluMEc+lJDBE45QZJ4OOtU/PKA7SDinWurRbijrtI9elAGkURH6e3vmkjuUYHYyuFyMhgRkcdfrkVE86MoYNwegzTbJEMuFCjJydoHUkn+fNACXq7jkEVnTt1+bB7E+tbd0qYK7gARWRPb5yFcY9qAMHUZmZNoOcE8E9a4LxLN86qWxz247V3+o2xZmHA68g5xXGa7pQkwRIVf0JzmgDk2cMuGk/eA/eHHFPtbqaCYeVIy7TyQetMnspY3YDDAdMiqN+Wt42Mnytngf8A16AOz03xKxfEv7xRwQa7XR9bt5HTOAT2zyBivFNPuVjYFT1yMdK37K+IHJJIHbvQB9A6dcW1yhV9rKetF74RiuVMtlLtJHKn+hrxzTfElzbSLjORwAtd94b8c3XCXEauMdB1oAyte0i60pytym0dFYHhqxMbnCqG3Hj1r0TxNrNpq+leWocSk5KHt+PpXK21ht/evgHpmgCTTYPJVTkZPX3qxeFVicMSMd6EUoB8rYB4zVDUZTIp2Ehe/vQBwHiSV5b1tx4HArnJhxwRmuk1+JlvpATnisU2rTdABjrnpQBmQwvNIdoOPUV3PgfwO2uzPJK4tNLtx5lzdOcBV9B79eKveAvB763K8ski22lwDdcXb8Ko9Ae5qP4meNIJLRdB8OJ9m0S3Yjjg3DDq7f0FAFH4jeO4Gtf+Ef8ACymx0KEYYDh7k/3nP9K8f1G5+VskEgEHmtHUZxsZm4J53dxXF6pqBkLKrHjI470ANtpioz94HtjitS3kzjaQfUVzVtKUYAnj+Vbdm+GAABoA3bfdITHgsTwAByavWqg7d3XNUbTbtyvTHbnArUt1y2QM0AXIoz24WrsSZAz/ACqG2UEj/JFXbZQOOPX60AdL4aztZTwBzx2rfK7V5HXPFYnhpSJCvGCM89K6YxjBA47jj+tAGc0ZJyTz2HbNIzCKFm7KM9K0ltWlbbGpZjwAB+VW5dAlMI81tqnr9KAPP75yzlsksTnGOcVQNvNIcheR/ERjiu8u7C1slLDaT/eP0zWBfajDGpMWD9BQBif2VLKitzjBOQO1SLaw24BlcfVjVe41qeTzFQY56DgVi3t7P5zK5/A980AdLpl5aJOGMQd16cY5rfj1G5bCqyRjGRtHSuE0pxtDKvI/WursGJC7RmTGeT+lAHQWl1PvXzZW5BHWrwmlBDBmYHrntWVBuk5wRg8Z4JrYghbyckEEjgGgDQsLuRG+Ylvfua0FvGzkfKKxIi277mD0xWjEBwuAQO3XNAGrb3rmdY93046VdQiRAvBKjH+fasy1i/eF/m64AoNw6Sng5z0oAuR2ri12E5CkrgnPQ4H6VmG2m81yqnOevatA3bod4wEYfNjnaeBu+nTP4H1qUSsBh84H3unFAFZDIiguMAdc9qtwS+UP3QOR+VUp7nyyx3E4yenFNsLhZl3c8n0oAs3uokFwGAI6+1Z39otAW3EFQMU/VIyEc4ySfy5rHu3OGGSCO59KAJ7vWlkJ3DBI+XJwDXJ6/qMkYDpjcGPB6YIqLW7hokLI3zDJGT0rnjqS31qY3JLDpu7mgCC61q6VGwkJjJzgjFRPqUV5F5FxAUPUMPmGap3cqOpEikj2rKnZ7dlEbKyMud1AG3bW0Rk2IxDHkY6VoJayZBB+XHQ1yslzKiLIFx6qDmtnQ9XlLZky+DkAngUAb9ra3CYdkbOedp6ZroNHSRWUkMWPSk8N3VtdlQPl56scj8zXo2haLHdyKsYSRTgcdD9fagCtpdr58auwycDtWjPZSBOI3APPAzmu70nRbWxUbY1dx3Iz+QrYVfTgegGKAPGby2K/KFZT1PH6VTktMK3y4yM4r2W/0eyvkImhG7s68MPxrj73wxPFeCJcyKx/dsvf60AeOavpUs90DtYDHG0Zz7V0ei+Awtp9t8Qyrp2lp8zNIMPIPRR717Ho2gWelK1zKsZnCkmRuiDvjPT614t8ZPENpqeqp/Z1xO8MSlXLN8hI7qPT3oA534g+NBcwR6TocX2LQbc4jiXguf7z+pPpXlV7qUZDMXXj3p2uXplLhCQM9PWuNvpDkn+ZoAdrOomVmjib5e5A61zk7DdgVZlc9zyKpOcn2oAbWrpU4ZtjfeHT3rKpyMUYMOooA7myO3BI474NblqpOCOeO3aua0WcXManqe4ArqLE7doPI9hQBrWqDaG5yTn61ftkGVx69PWq9oA4AQ9BWnbITjggegFAG1oSgOS/zD0rp44wQTyBngdc1gaQoD7QM9McfzrqbZMEeh9qAOx8N6VDDZCeUfO/JJ7D0rJ8RM5Z/wB6FQDACdTWqurRi1Ch1VQuMf0rl9Xu12MMqCc/X/61AHD69cHzTsXaB1HWuMvHJJcFsZwRiur1di85Krn0wOT61gT2U0zkCJljx1IoAxX5b52Ab1HY1DPEXYBjuZuy1otpB8zMkm9VOW9M9qnMkVsQ6su7uoHf0oAu6PpsrpEkcRUdNxPt1rrdL0MxlWMjccHnArn7HWJZFEaxpEPXPWteLUDJFkysWyBg9qAOsh0uKJQCFGcD3JrR8uHbsbAGK5eO9y0RbP8AT2rTSQCDPJFAGpbRQkgAcevarqW0YO3JPfB/rWAtybc71Zj6ZNLcavIsbMfpn0oA66zjUAgjtisXVEMVwwUnA6d6xLTWpXn2ox2nr83Q1tQs16wLtgHqaAM6a8uYucrtUZwR1rItdcuVm8nO7axQFvTqP0x+VdpLo1u8WSTux941zd14fht7otvYh+MZ/iHT8wT+VAF2Ey3UeZCVyM8dTW9odsQzFvu9ge4qhpVsgQkEjHetOOQJj16ccUAS6jbpJ8uQFzyfpWLNp0TEnbjjmrM0zPnJ3DP4VTluXjRgRzgnjp+FAHG+J7WItKm7bs7V53cyCC6UkA4Ir0fxLE08bOSenIA5rxPxUjR30ux3wODz0oA6+bTo7yIXMOQD1GcjNV73Q5Vt1KDc/YEY/SuU0C9uosjz3CnGcE4rtbXVZNvyzBwB8wbnFAGD5PkySRzLjCDAPrS6ajwLsBAXP41sz6hbTNvuIcE8ZHIqxDY290srRMPcDGKALmiTHzVUAAg44Pv3r6R+Gdr5WiLcNndIcLnsor5x06weF0IVnBfO4V9Q/D9Ufwrp7AEYjwQR3yaAOiRR/k1IKAMdKKACkZQxBPUHIpaCQASeAKAPOPiZrLm2ntI3K26DDjON5+vp7V83+Ib1pWkBYgA8CvZvHM3mwzvgklyc54NeF66dszD8cjvQByeqSHBwcVzN4+SxA471s6vLg9efeubuWBcnOT0yfSgCnMfmNQ0923MTTKACiiigDY8OXfkXgRvutXfWP8IOB35ryuNijhlOCK9I8PXS3VrFJkkgYYDrmgDrdOHK4O72Nb9oVAG0AHHJ9657T+qkEhTz1rp7FWkwp5B6+5oA29HT5mJyT1ziukjTCnqCB1rF0WMjjjFdnp2ll1WWbKjHSgDmr8SSkRxAjFUzazpkTuSv90n+vrXTatNBaRk5UAZ61wGveICNyxg4PGKALGoT2lrG3Re+W5Jrl9U19cAQgnB444H4VlalezzscMcY79BWM0e2Ql33c8gUAXb3Up7kkMdicdBxUFlB5pZSXZs55qB3AA3jKnBC9BipLOeZp8Qow39AooA6C2tirAMTu44rXt4ZNwEWNmOQaraVaXRKnaQ2erdq6qx01+C7nHUn/wCvQBVgZtqqynOOfrW7ZBmCKQQSueRnHtVmGGBQAgUgdN3WrsawiTIZfwNAGRNEytvd8cZNYuozM6uYyduMAetbt5Kk84iRlCDIJzyfaoJNILMAJRzxjHJFAGbo0U0jMflJznPtXX2G9GC5AJ65NJpGnrAfkUEdyau6lahG/d8ZHJXg0AaBKqihnAB9e9Zepwx3THy5cOTx83QjkH+VZWprdCElZXIHY96y7J7g3GMsVz2NAHSxyyJAsqbRuHIPGD3H4HNPtJ2nJzwSevqKyVhuVml3bymQ+AehI5A/n+NdDpMQ+YuBjpjFAFeRCjAHgsORVSdNwYg/KeAKvagjCQheR1xmoLcRHHmAjPvmgDB1GEzQnMYB5ywY5bPTP06V454m025e9k325Iz09a911W7t4w46DHFcHd39o00iTMN3IPy0AeVrBLChPlsqj27VVs9SdJNrDKk8kcce9dhfyWWGKMyDuMVziPpkkrbGjJ78YoAszTGZhLHxGRhQBSW8rwq/lybMj1OaUwCNB5DO4boFGePrT10yVIhLgsW5ODQB1Wha9LCpW5IkXggjkivoj4SeJrTUbA2KTKZ0+dUPB29+PavlG23xgAA9eRjj6Zro9A1G40+8jvdPlME8RyrKeRQB9pUV5x4J+JljqdrHFqzR213jBZf9Wx/pXew6jZTIGiuoHU9CsgoAtVmeIr9bHTZDuAkkBRB7+tXXuF2MYiJGA4Arzbxdqk/nSeeRvXgKOw9qAOF8aXe1fLTqwyfY14/r7g7sNurt/FFw87sWZiSe9cBrGQrZzwOBigDhtWky7c5BrBuG4wOK2NXJ3nNYM5+b3oAiJyc0lFFABRRRQAV03hC7a2mABO1jgj1rma2/DzHzo1AGS1AHrunESRowO1STz/Ouq0hNy9Cc8ciua0WALDEoGTt5Oa7LSoSFGRnHWgDrvCVkLi9jQg7VG5gOldT4ou/7MtESJSSwPIHSsvwcywGY8GQ4H4Vo6vP5gwcMB0yaAPMdYuJbksx81ic881x2omGNiHVmkx90N0H1r0TWoJppDsHGex/zzXLzeH1JzMQWHIBNAHEzySP8kcYXcO1Mg0+5kVmcmMZ6n+VdTepa2QZWIUDoF55rCuNXz8tvEA7cbm5oAdHpkcSyNPJvKjIYnFKl/a2hHkLvbAIAP9ay7uaWRmMjBs9+wqGORABhD8vIoA6ePW7hjwBF3ARc4rVsLm5nYb5pdpPAz1/wrm7VyyhjHhgRwTmuk0qWNUbeQpABC/1oA3YCQVVmwBgnFX2lVQ3zZx1+lYs91HFECX5YdutSJKAi55Y88mgCwGEUgYbhg5HPGKtrftJIir2IyOnTmorWF5Y9zDcDnJxV21tlQ8oMgenSgDWsbmTKFXI6Bj3retx5wBesTTYC/wB0cegPetW3zFOB0U+/agDQbT4JIgjRgj3qKPR7SOQsseWb17VfjdS2GYYB6jrUq+SW+Uj8DQBWayiAI2KpY5OBjJ6f0/Sq0tqANqAlug9c1fmdU3ZIPt6iqy/vydoJHTmgDk7oTRyMzscgms17maL5gdvGfWuk1O32nJ4Jrn9RiAGB9/0xQBiX7mQF+3QgmuW1C2LO7BNp9elddJBLKyjaQuc5Oao6jYTYI2ZGMYoA8w1fcFcFcADGcd64qW1ZGZkyMevrXs2o+GpLiMM0RI9q4HxFok9pI3yHae2KAOd0rULmH7rEEGu00TWlEYGoRblJ5ZetcHNBJCxYLyx6DtVuKR2VMM2/HIJ60Aeprb292Va3cN3AB5FMXSZ4XIBLF+uOwzXHaPdTJIoDNHIOAQea7vRPEzxShdQiBQ87scj60Aa+lWTLISrFCQMgjGP88V22jQ3KFQJlz2JBBqjpjWOowM0MitvOB2K/hWvFaT2oV1UvGOrHqaAPRfDN1JFD5dxIZMjhs4xXKfEyMRzR3CfdcYz70201iO3Qea4z2FYviXU3v9qMcopODn9aAPP9Yj3KWY5PtXD62uFIA7Hiu+1IABhjB7etcRraqwYgflQB5trI/eua56b71dJrq4kJ965qU/OaAGUUUUAFFWL+zuNPvZ7O+heC6gcxyROMMjA4IIqvQAV0XgyAzapFkAhTmudrtvAVvsV7hgeTgUAeqaOoeVV7eldpp0ecZBUDjrXH+G0LFG4Ge/rXovh+we7kCKuAOpoAs2hkiy0I2t7Cta3LTxj7WcSAYPYHj0q1ex22lWgaUhQByx65rz3X/FckjstlmNPUjrQB0GtX1pZH52UMMkAdc153r2uy3AcQsIlJ5A5NZ95qcsxBdsqefQZrEvZtwOPvYySP5UAR3EokYq8zHuc1WFwI/mjAJHtTjbSSscKS/Tr2q3pujSh3DNtBByKAMd7hmZmYbif09qsxiZ0VUjG3HBx0raTS7W2JMhUt338ZqK5vbaJ9sQLY4yBgCgC7olvcTyLkKAOxAxXXR6TvUPMcE9kGOPauHstZl3BYyIhyc4rci1S5c7zNIzcBeaAOgTS7aMsNhwnQnnmr2nWts78nNcTJfSk+WZZBk8n3q1Zu8c6bnfnsG7UAepW0MXkrtUbTxjrUYs5fNOARmsbSpSER1b5fUcf5710iXag/KTtzxuxnHvjv0oA0dLtdpBcgk9cdvarV9YhpFI5X2qpY3JGMHGT0rcVg+Q3JIoAyhBIqdTikAAYYODXRRIhjHHamPFDnOwdec0AYUcbMwwCFxjBrV0+3APzjp0NW/KXaRjqMkelRONqnnA6daAMvUdNL6nJdG7n8hrdYPsnHlKyuW84d95B2ntgDuBjDvNNiSYOSTt6VvXcvzMGbPpXPajdNGzNyRnjNAFCSSGBy8h2jtzWfdXltIXdWLdORUGo5uFdlb5jzjOKxrdChZCx3Y6GgDXh1WyUPGzk/8BxWLqdxYSq3mfxA43Lnis28+W7l2g8jv61PLDHLAN2AGGMkUAcN4i0yy80y2rRkHqB1rDOmQy8o5DEfka63VtIZmZVPy9iTXDXT32m3JMJJjByVYcfrQBaFjeWkisAWA53L2FdBaXss8WXVdy/e7HA71kaX4gtpPln3RM3BPUGus0iK3nbK7SPVecUASWd7LbzLJBKV2dP/ANVd9pXjpFiCXSszYwXA4H4Vw11os9vv2AsuQciqcIkgkYHqBkepoA9tt7Sz1iJbiNw+7o61BqWjz20TMQXjA42joK4Dw3qlzp1yGt5ThuSp+6a9o8Lalb6/bNCwCzBfmQj9QfSgDyLVFxkEgkcVxOtgKGA9+TXqnjjSv7N1GWJf9W43R5FeX69lkZQPbk0AeZeIQWkODXLSD5zXX65GDv6nB7jtXJTjEh9O1AEVFFFAHoPxr0P+xPGeoG6uHlv7+6nvdjNkxQPIfKDf7RGTjsNvrXn1bfi3WrvxP4s1PV9ULJcXlw0kgIJ8oZwFx6KMD8KybqRJZ3eKMRRnhUHOAOB9T60ANiXfIq+pxXpuixCGzhhGFPBNee6PEJb+IHoDnpXpOkAXF1GB0HGB3oA9G8MQHykJGBXt3hiwjstISRx87qWNeReGI1zCCAQSM17HLcCK0QKRtC4X3oA8y8V6lLfXkrOf3YPC9hXG3QaTIVXLZ7c5NenaloK3kvmgGPPUev4Vl3Ol2+nQkuVUAZ3E4oA88XRrqUKHXy0POW61LDo9vbxlnRc47nNXtb16KEulsFkIPB3fLXFalqt5dMy7iEzyF6CgDYub+xtXCh1dxkEIcgfjWPc6/JKxS1URDOAwPNY9wwJKgDHriktxyGk4xxigC+90ZmLzsXfGQfSoCzMpJyBjhR0NVkV5Lgddv9a0Fgk8rBUgMcArztoAfbufuxqDzz7VrtNtSJQfnJBJ9BVHS9Iu5pSVUDtjvitux0KTzMTuNwHYdKAFZA6oMds8d/erNtEWnynUeg61rWuk26FvtEhYMMYY4rcsrazSMeXgkYGDigBNHjdY0VwcDgbq34lBOSMY6ccGq+yLyzjALDPUc1JbyEttKng8H2oA17RSsgAOT1FbdvKUcK+AD0rO0aCQ8sDg/rWndWxBBxx15oA0YpY9g+ZR688U57iHG1mGSelY208Yz6k04DJGM+n+RQBrNNGFwDVN5txIT7vP61V2HHAwe1X7KDLAvzxnpzQBnXanGc8njgZrB1GHfnklscen+eldhqNoH5Xg9uK567siJRu27c9uMUAcfcWTiYBR24781mXMEvzO0ZBHbnn8a7WTyo3HmMoI/L6YqrJcWrSBCV5OSPegDint1mALxgOoycVXf5FIYDB9R09K9BnS0McchKHcvIx0Oa5/VI9OaMgPCUOeM0AcdeLgEuRz0z2ri/EESyxHcoPHUivRpdNtpEKo6tk8YbtXP6toikHDjHTp3oA8eljKT424HWtjS7q4tXBjl7+tWNf0qW2lLlCwz2HNZ8GfuunTknHSgD07QfE0jW0f2wZ2nBI5H410MUFrqSmWN1wy44/nXl2k3H71UDY3jBGK39FvnsrplDlCCRjr9QRQB1smkzW7howzAcgY5Nd94AV7O6+1SjZxgL2/EVn+EtRs7po45QIpSoxnoa7T7AuA8JAA56cUAZnxOC3FlDMc+Yhx+BFeHazGdrAY465r1XxrePM4gJIUDk+teaasu5WPvjpQB5vrkRG7ofTmuIuxiUjivQtcTGc4x61wOortlx7/AI0AU6KKKAPpn9snXtOa50bQLVI/7RiLXl06KAVVgAisQOScE+wx618zVqeKNcvPEviHUNZ1N993ezNNIewz0A9gMAewrMAyQPWgDT0oGIb8kEn9K9K8JRjcrcA5xxXm8IwURfyr0/wkgEUYBP0oA9Q0QEvFszuzgCvVdOgc2cZuPvjnANcr8PdH3wC9nXCYwgPtU/ivxKsNw1rbNhFyrkGgC/r+swWaMsJDOO2eBXk/iTULi9ZjOxKYzjPatO7uXlcFQXY8kDvWbPpd1dJvICBTnNAHHXg3EKnze2OlZ0iMWCIpPOAOea7n+w4IwXmcyHPPYU14bS0jVvkQ9s9s0AcVBpFzLtdF2RtxzV9NGKsqyudg7CtW41KHzAkSb2B5zWZfX0plI4VR3HAoAtC2srCMfKqsO56mqd1fRyOVhjJ4+92qjdSbmwXzgd6fbKAnbb1Of6UAaVnf3J4VtiYGOOtW7e9uG8z963TBB6isgSl5hEobae68YqWVij7QxHGc0AbUF5JuAcgj6/5zWrDM8ihdxycYJ64/xrn7OEtsZl3D0HQGuhsYj5YZhyD1/rQBtW5YRphsYGDz1rrNKIEKk7Seua5GHhSoVsZHHtWvasxgG1iAOeetAHaWl8I3+ZRgjj3rZLCb72Me5ribR5GKsO3bqa6KyuiFAkBBzQBvW8cZBUqPp3p/lRKThBkdqgtXjC5Y8+lWjNFkYK5+tAEZjQE8Dnrmgjy8lRg/SlaSIgZIHPSqcspbhOATxQAy7ncEYYlR7VlXsyg9OTzxyKv3KH7z8c+n5Vj3K5Y8HngYNAGHqIDucjAGcHFY3k+bcqOWA9O1dFdWxcHGdpGT6mqCI0UhXaQCOBj9aAKF1wCBxx09feuX1WLG8hv3bc4711N826VlGd2MdM1y97KxieOQjd6evpQBzkjlZDsdgcY47U37ZcxrtZ946kMM1JdQojfLuBz0rPn4XkYYc7s0AQXl7FMrrMmwqOGHQVRtooZwQBG+DjA60l7krkHPJOMc5rlBJLbXrMrMF7A96AO2t9GiMoaEshJGO2K0LrSrqzuV82PdHIoYMBmud0bxBNGwEw8xOOK9M0TVbLUbKJWIWRTwr+vtQBlaNdSQAoRk9jXf6P4wa1EdpO24McFs/dFYV1pkE8W6MKkp5BUcVz11Zz2soMikbieexoA9i1DSoNY05pbVlLYyCK8i162ktJ5YJgUZDyDXa/DbWmjvks5mbbJwpPr6Ve+LekKttFqEKgZba/A5z3NAHz7rq7VfArz7VsmUknvXpWux5DY/lXnGtLiU9OuOKAMuiiigAp8f3xTKfHy2KANbS1DzrxkZr1fwXbtcXVvEPvO4Ucda800CHLDOBzxnrXsvwttGm8Q2YRd21txB9hQB7rdyHTNAMVovMMYVQPU8VwUGkyzMXujyxJx1616RcxRi2k3EbnHJNeXeIfEwhla3tjyOGc9KANGcWlhF8zImPU85rnNR8RxQkiJAVIOC3ArBv7udpX86Q7z1G4H9RxWXMAQAWLZ6nv8AhQBbv9XvbhTlwin0rGa6klGXOdud2BVh+VGNwPYDtURjkKmNVPPcck0AVjMFlKqc57jrTJGLR5429D3yavw6XO0WPLYZHJJqePRJMbSeByAO1AGRFHjDMeR0FWGDnKDPzc7TXSW2kxQrkrk44JOPwxTZEghJ2hOO/tQBz0McizKih+5JxU8kM/mR70OxlwK13uooJQ+3G4flUGr6mfLjyvy4zjvQBt6Npdw0S+YqoqrnGa3tO0zdPhpFx2wK4y08TyLH5YYIf6fjWrpGsyfaQVkxuPzHH60Ad9Bp0MWQo3kj8vwpiKUdlCDjgA9vwqhYX0wlz5pIPXHOfpXQWEMdwTJInXj2/wA4oAm0xGa4X5eenFdDdWrLCrKB0zTNLjto5FH3cdB1recLJHs7CgDnELYG0Djg54q9DkoGK9ODmtOC1RR0HOMcVcRIVByq570AYSq28cAirNrCZZB8uB+VajR8cKCO2aWMKnKgZx0FAFK/tGMR4Gcetc3dROH2tGQPpXYXU4VCAARWLdyq+4kDAIHJ7n/9RoAx0KqihiAewJokNsIyWCEn1qjeH99k9SeB6/4Vn3hbYyL7rx2FACyxWk8nKgDPBBrC1XSLYS71JCnvu4BpLoNs/ds4Pt61VuZGmgZQWVsHOKAMi+0dGOUkYc9+lYtzobtExV/mJ6dKvPPOkjpK3yjjntWfdalcQyDk7Qcde1AGLfaXeQSZ8rcrcdeeK4/WYmW5zIpXtgjpXov9qK4Lzcd+D/SsfVbyyuWC4UMf76/1oA4u2wkwKsMfTpXW6RP/AKM+ZNpLYHPXjtUcWmWk7FtgC+q/1rW0/RJo7WdonBXHAPGKALela/dadNHEMSQseVc/5Nd9pF5Y6zFtAUP0ZCec/wBa8okgljcebGwfB564Na+liWF45YpChU545oA9P0jwy0Wt209oSIopN7D2Haun8cypc+G71HAyAffkdKreBtbhltlhuWxKRkE4+Y1qeOrIy+HLl7dQXIxgfSgD5h1xcbiFGT796861peW4r07XIyS4ORjjBHevO/EEeGOR8wyKAOaooooAKfFneAKZUtuN0oBoA6vw7FllyvX9a+k/hZpCaVZx3lxgSuu9mP8ACuK8M+GuknU9btYmU7FO9h7CvYfG2tnT4YNOtiVMoDy8fw9gKAN/xH4iN2Xit3KW444PLe/0rz/Uts7ttwWJ+93JpltLNcDbEMnHUn7tadhYxW58yY75G5JYE4oA54WM8rYRSFJyM9DV+HQ3RGMzqx9PSuhlMabm2fOOQAaa0UsxBCYyeSf6UAZEemQRvnAbaclj1NO8mBCoUgMeAU5rdg0k7R5o3k9uw/CrkOkoFBKYI6YHOKAOXKudskcTnPGW/lSC0uHbmMInfqM8V2jaYCoUqw4J5HFOGloUztPJwfagDiLjTrjBffuUnoATxVR9LuC2OCWXABH+cGvRpNMRsYQjAApg0zc+WHQ8cc4FAHmw0eXJabhew9ax9ShcM+AOuRXrGp6axjwi5HQZ71xmpaQ6w/MGO3uDigDhZYH+Uvwy9cd6uaddyxyrliADj8K2P7KLoqlGB9xUcehXDH5ImwT3PWgDstK1CKSJFR8MByp7GupsbnZHtD5DH6Yrzq20q8s5Ekf5OM47ntW5pWrbA0VwcMh59vSgD0G0unQhmJOT1JrprW/O0A9+OK4XS71Lh02YbPpwcetdl5BFujgZGBjigDetpY2CkP161Y86HuRnpXLCfAxg4B70sM+6QlnGOnFAHVmWPZ8p9qqvOBkKR71nRTKwzk56U+2/eTZP5kUAOupWLcVhXzOGwAQQO3TFdNfW7JGMDJ/irmL4FZMjr70AZcpbeSDuXrVKUv5bAhfTj3rZt4o2hOVJBPOOwqK40+JlzGxX8f1oA4+ZXVSDkDOASfSqty/lOdoyAM+/Sul1HR3aMGKXg85xWLqen3IT5QpOduc4yaAOfm2zSKzKHUjPPUVk3METTFDkkZxz1+tb76fMIXdozubOQeh+prEuZGXH7twAu0jbQBymtRLGzbfl54rkL53+1gBicHrmu41ld4LSZUDuR1riZYZHmkZuF7UAS2l1PDIpRmxnHHHPvXcaJ4gENrtuo8LJwGFcbBHlQDznnmrzKGWKNtwYAnmgD0Sze1vGBjKOQNpU9RVz+x4mT/R2CcZweRmvNrK4aJ2feQw9OtdRo3ieWGQR3vzxBgM9xQB1UJmsgomwGXBDA4Fd54Z8ULfsdNuPmkRPvdQ1craXltfWnmIyyRj+HrWMlrcaVfxX9uThH3kA8gf1oArfFbQP7M1I3EIb7PP8wI6A9+leJ+IYvvEZr6o8ZWseteFbmMRjeiLcQ/QjOP6V8zeIYBsIwc59KAOCYYY0lSTgiVs+tR0AFS2wzMtRVYshmcCgD3H4P2/kWl1dkDdIywocdO5/pUuuW7aj4ovpxlQZAGfJOSowOM46Vb+GVoZNItEX7oJkbHQVoauiW97cKAVRmJz/AHs0AQQukEaLEAMck9OfpVq2nkuGQoQFzgHrxWfbRNO6gqR6Y7Gut0PTwrL8mMYzx1oAt2OkglGdSQRkt6fWt6304AZ2ZGKu21ryOACBnHStKC2wzFVAJxk+vAGf5flQBlxadjnClvT2qZbHqAOezf8A6q2EtcfKBj0x0q1Fas3zbeOf5dqAMMWHBwu4dh6VKlif7pHXtXRQWQKqSuCeqg5xViO2RDkigDmDpzMDuToeKli0onBdcDGQc10jRDK4UY53Ficge3rSFfmAHXHQCgDnZdFRoiHUkg5ArKm0G2JYuo9/YV2jRnaAcY9jVaS0SQD26gHrQBwlzptlCpwkbMfQdKoTwwICY4hgck9q7ybTIifu4J5PtVOTRYzwBw2MDHBoA85kdDuPlPnHJxwP/rVkDR5L27YocKTxXpkvhxTu2D5Tzg9KLTQmikBK9aAMbw/oUlhMGEnmlcErmu/aUNbKCMEjJ9qyrfTnikVwuNvp0PtWtHbN5YGOvGc5/GgCpF9njlHyA5Per6fYiwDKu4joeDigacC7HBwe5HNJNpsIZWkYblHBA5oAtqsEqYRBycdB1pIFSJ8hcH9KrR26woBEx9TzVK6upIshWyx/UUAdFdzwrF833Tx9a53U/s7KSo47Vhax4hljjZGj5xziuWvPETeYV84occA9j60AbVzemBm8t9o6A9OlVLi/dAhWXzMoPUH6e9YMmqB2/esDjoV7mpInWdyQSR1oA011OTa43k46d6oXGrvvJKnpjavQ1HIsqgHaeCcjp+tVmhYNhmJY9DigBDq0e0I+3A65FUriaJ2JAwMEkDimSWa7ySGLdQTUF1G0YVmw4XjntQBl64YXhKYBfoMjtXL/ANkrMPkIXJ+6O9dHd2xvGI2lSB0zx9asabpTKeE4B/p3oA5ZdDnhHmBdy9azGRjM7HIHPUDivWri0t4LMq4KyHjOMjHvXP3Wg7gW2oykE5xj8KAOIhjCfMWBDDj2pnmDncTu7EVuXeiT26oVXIPasKeF0YiXPsTxQBf0/VLm0uFaFypXsDwfrXpXhXV4NWhZeFnUZaM9/cV5FCGDj8sDnNdD4faS2vYZICVfOdx9O9AH0FJa7LKwkUMYmhMbjJwAfavmTxvai31K+h2nashGe3evqbQr6LUtKRkX7o2vH/dOK+ffi7ppsPEl6GA2SESKfXI5oA8PvVxN7VXq9qaYmJHrVGgAq1p43XKjHXiqtb3g21+06xHu+4nzt+FAH0T4Ot1stEt06M0au7Dtx0qrr/8ApN35qLhcADHoKje+C2sVsndN0hHHy9hWjYDzkCMNy4Aye1AC6NYkshxlumP6ZrsdMtipT5cYxj2qlplupVQVyR6jGK7DR7IsASuFHpQBZtLfIVlQnjgDpWnbWR2jeOvYVctYQirhT7VY6Kcdeo46GgCrH5CXa2+4faDGZlQg8qDgnPTqRx15q0F2nHVcdO1OLNyOQM5x703BOe+KAFGckEHAHShVYjk5ByQQOB9aULgnOfxpwUAnGev4UAIBg8gc00gnoCR6GpcYPJOMUMvGcE+tAETA+/HvTNoPUdPT+dWGODgcmmSBiCI22McYON2PXj9KAIHjJ5A5qFosgepFXghOQDjBpVgPfpnjNAGd5GO3ak8naeRzjGO1aywL6DpUcyYQlQWZR90EAk+nP9aAKSR7tuAcirkUAKAgZ/CpIrcFgc8+1aUcYMZGBnpkf1oAyQpAJ5Hoc4qGeBZfvKT9a1DbKW+YlhnJqRbVC3PGe1AGKlnGQAQ3HShtKicnkjJzW6LaNQMdaWOEK+eeT+dAHB654aaRiUAIIridV8NSLIu5STnHQce9e5XEAfluRWPd20QHzqD3yeaAPCZvC0ySeYqEbQec1D/Z19DIijIHUgjtXt0ttbgEsgAHUngD3PtUT6RZyt+8UMT2POKAPJYkvDGVcBlAxg/zpHilkz5keeONterT+HrXY7IP4c7az73QQF2qB1zxQB5u9p5Z/wBWWyccjoKibTXlY/JwfftXbPo7wMxkQYPGc/0qhJBsfZGuR0I9BQByx06NSTg8HA5q7Y2sPmZ3FDu53Y5/Cpru2mQbI/ndjwOufpUUFvMAH3HzNx7ZoAZqqCS7YoAVC4P+NZDQsMMhxjgdwR70XzPbXUnzttbK/jmoRdEjcDkdOaALeYHQCQAHoSBwKpX3h+2vEYGMHj5SOc1E12AzqCwf0Bq1YXj4RnO1e2fWgDgtT8N3NjcM8YMkQ9OqmpdLAikBf0zjvivTIWjnJEwB7EEZzwP/AK9Y3iPwz+7e6shyOWQDrwMYoA0fCGtmzvkwSIn+Rlzxg1U+NVgLu1a6UAyRDk9yMVyENzJbvsYlcdPUV3GqTDVdFQPhhPb/ADZ7sBjNAHy9rC4kYYOc55rLroNfgMd06nOVJzXP0AFdv8P4Nscs5OC7BR9BXEV6P4QjMWnxIehGSD60AdXp92Z7lz2zjPUCu30f94seOSe2etcBoMZ8wBc4z171614T00BY5ZAwJ+6KAOn0OwKqjS8HqFNdVbMqkDv6gVkQkRgA4B+tXrWUu3U/40AbaNkjkg/WpMkkeh7VWgdDIY/n3BQ3KnGDnGD0J4PHUfiKuoOmOhoAQDL5HXH5U/HGeMduKeoOeMgfnSqMjjd70AJ0AAzincD8v8mgKQc5AFSKpOBk49aAGgZwT3GKXBI6ZHpUqx4JLdfrT8eg/CgCHYVwCePSlCKABngc+lPJwcjJPYCo23dAcc8e9ADfkThRnqcH1pDKSRgAUrKATzx60yNXZQ0kW1u67g3f1HtQApyWY9fb0pGUdRgGniPLdeaUoT9KAHRSEc9v881ejkDKMgcVS2lT057jPSpIwRjnj6UAWxjd6k880pQfL0zUAcqcZOP5Ux52LFQ/KgEgds0AXQoUHB+vNRlgpyeM85qssrcEnpTmO48/UUAEk+0EKc5qhLhiST9B7VPIDzjr1zUboe4zz1oArFSfXApmF3E4GMVYKHGAevSq8pWORI3ZRI+dqk8tjrj1xkfSgBssgCleoIwQeeKge44w5x39cfhSzH5goyR0qjKeTzgjkNQBYldHG1gD6cVl3NpCfm2LnpQ07Z+Y5GOv9aikuV28HjvmgDLvLBedpypIPXkVlXjGANtGF9hit2W5BOCRj2x0rMvpEkDAAHIPGKAOP1Z/MJII3MRj/DFYHnyLcZxnPtj8a6i+to33AjO0cAjmsa8hRsg4Py9c460AY00u6bey59cVZiy+3DEfLhcmp104E4yWyO/arcdiIdwK5yO/8qAH2krvN8pGFOQR2rp7G5WUbXxvHAwOv4etcfCohcrvAJwRg9K2YWcIsicMCDnpmgDC8c6M0DG9tkG3+MAdPpTtJm36JZbj9xiM+2a66R4tQszvUEYxIvT2rn9UsjpUCwIP3RG4H60AeC+MLfytRu9o2jzCeR71xjjDEda9K8ZQBr6YkEh/mB6151ecXDjJPbmgCEDJFemeGBizRu+AKKKAO48Hwo92gYZCnIFev2Y2QArwcce30oooAuWrFyN3OcZzW5ZgbgOxoooA3YU4XJJ4z/KrC/dGecnFFFAE6AZB9+lPVRx74NFFAEgVeTipVHGfxoooAaVC7sdulKyjJ9hRRQA1gPMAPdcmkUZBHTHFFFADSo8zHuRmhcFhx1Gf1oooAD/EPfFIegoooAkQDjAxgVYjQBUPctj+dFFADGUcn3xTG42EcZoooABGpOakQAg5AOT0oooALqNVZNoxk/0qF1G4j8aKKAGMo2hiMnIH51VlUDPXtRRQBlycuynoaz7s4AI6kH/CiigChKScE87gc/hWVqUzo5RcbfSiigDAku5UaTa3RhUN5cSrwHIGBxRRQBQimd4/mOcNjp1FQX0Sujlhk4JB7iiigCnZs6ucO3Jx1resFW4hfzVBKnINFFAGO42uzA8sSDWxafvbSPcT1I4oooAdZHbqcIAG2RtrL2I4qz4shRtMkcr80Z4NFFAHh/itV87O0fcP868r1AYuDjvRRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pericardium is clearly delineated by air surrounding heart and air in lung.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gerardo Cabrera-Meza, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_0_6144=[""].join("\n");
var outline_f6_0_6144=null;
var title_f6_0_6145="Pinazepam: International drug information";
var content_f6_0_6145=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pinazepam: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4302623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Domar (HK, IT, SG, TH);",
"     </li>",
"     <li>",
"      Duna (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F4152021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Benzodiazepine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F4152022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of anxiety, insomnia, convulsions, and skeletal muscle spasms; aid with acute alcohol withdrawal; premedication prior to surgery",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F4152024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anxiety disorders: 5-20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insomnia: 2.5-5 mg at bedtime",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4152025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: 5 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10517 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-7B7E1375F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_0_6145=[""].join("\n");
var outline_f6_0_6145=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4302623\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4152021\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4152022\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4152024\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821137\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4152025\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10517\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10517|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_0_6146="Older stress fracture fifth metatarsal";
var content_f6_0_6146=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Older stress fracture (Torg type 2) of the fifth metatarsal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 442px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This close up view from a plain radiograph shows an older stress fracture (Torg type 2) of the fifth metatarsal diaphysis. Note the widened fracture line (white arrow), extension of the fracture to the opposite cortex, intramedullary sclerosis, and significant periosteal new bone (causing lateral bulge of cortex). This stress fracture clearly lies distal to the intrametatarsal joint. There is great risk of nonunion with such diaphyseal stress fractures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_0_6146=[""].join("\n");
var outline_f6_0_6146=null;
var title_f6_0_6147="Scapular manipulation for shoulder reduction";
var content_f6_0_6147=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scapular manipulation for reduction of anterior shoulder dislocation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 489px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient sits upright and leans the unaffected shoulder against the stretcher. The physician stands behind the patient and palpates the tip of the scapula with his thumbs and directs a force medially. The assistant stands in front of the patient and provides gentle downward traction on the humerus as shown. The patient is encouraged to relax the shoulder as much as possible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott C Sherman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_0_6147=[""].join("\n");
var outline_f6_0_6147=null;
var title_f6_0_6148="Colon and rectal cancer";
var content_f6_0_6148=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Colon and rectal cancer (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?6/0/6148/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/0/6148/contributors\" id=\"au1734\">",
"       Miguel A Rodriguez-Bigas, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/0/6148/contributors\" id=\"au1707\">",
"       Axel Grothey, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?6/0/6148/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/0/6148/contributors\" id=\"se1234\">",
"       Richard M Goldberg, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/0/6148/contributors\" id=\"se4549\">",
"       Kenneth K Tanabe, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?6/0/6148/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/0/6148/contributors\" id=\"de5563\">",
"       Diane MF Savarese, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?6/0/6148?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      COLORECTAL CANCER OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Colon and rectal cancer are cancers that involve the lowest part of the digestive system: the large intestine and the rectum (",
"     <a class=\"graphic graphic_figure graphicRef58531 \" href=\"UTD.htm?12/60/13250\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Tests that monitor or screen for colorectal cancer are important tools in finding colon and rectal cancer at an early stage. Screening tests are described separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link\">",
"      \"Patient information: Colon and rectal cancer screening (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     This article has facts about the signs and symptoms, diagnosis, and treatment of early stage colon and rectal cancer. More information about colon and rectal cancer is available by subscription. (See",
"     <a class=\"local\" href=\"#H10049748\">",
"      'Professional level information'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      COLORECTAL CANCER SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The most common symptoms of colon and rectal cancer include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Stomach pain",
"      </li>",
"      <li>",
"       Change in bowel habits (constipation or diarrhea)",
"      </li>",
"      <li>",
"       Blood in the bowel movements",
"      </li>",
"      <li>",
"       Feeling weak or tired",
"      </li>",
"      <li>",
"       Low iron level (iron deficiency anemia)",
"      </li>",
"      <li>",
"       Black or dark-colored stools",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      COLORECTAL CANCER DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Your doctor or nurse may be concerned that you could have colon or rectal cancer if you have one or more of the above symptoms. In this case, a colonoscopy is often used to look inside the rectum and large intestine. Cancers growing within the large intestine and rectum can be seen during a colonoscopy, and a biopsy (removal of a piece of tissue for examination) can be done, confirming the presence of a cancer. Colonoscopy is described in a separate article. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"      \"Patient information: Colonoscopy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Staging",
"     </span>",
"     &nbsp;&mdash;&nbsp;Once a colorectal cancer is diagnosed, the next step is to determine its stage. Staging is a system used to describe the aggressiveness and spread of a cancer. The stage of a colorectal cancer is assigned based on:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Whether there are signs of cancer spread on a physical exam, CT scan, or MRI of the abdomen and pelvis, chest X-ray, or other imaging tests.",
"      </li>",
"      <li>",
"       The appearance of the cancer specimen when viewed under the microscope, after it has been removed with surgery.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Colorectal cancer stages range from stage I (cancer has invaded into but not through the entire wall of the intestine), to stage IV (the cancer has spread to distant organs, such as the liver). Treatment depends on disease stage.",
"    </p>",
"    <p>",
"     Earlier stages of disease (stages I through III) are referred to as localized colorectal cancers and generally treated with surgery, with or without chemotherapy. (See",
"     <a class=\"local\" href=\"#H9\">",
"      'Who needs chemotherapy?'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     Stage IV cancer is called advanced colorectal cancer and is generally treated with chemotherapy; some patients may benefit from surgery. The following sections will discuss treatment for localized colon and rectal cancer. Treatment of stage IV disease is covered elsewhere. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/22/40293?source=see_link\">",
"      \"Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      COLON CANCER TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The treatment of colon cancer usually involves surgery, and it may also involve chemotherapy; radiation therapy is only rarely needed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;The initial treatment of colon cancer usually involves surgery. (See",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/9/38034?source=see_link\">",
"      \"Patient information: Colectomy (The Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     During the surgery, the cancerous part of the colon and surrounding tissues are removed. The lymph nodes (round organs that serve as filters for blood from the intestines) within this surrounding tissue are examined under a microscope to determine if the cancer has spread beyond the colon.",
"    </p>",
"    <p>",
"     In most people, the two ends of the colon can be reconnected immediately after the cancerous part has been removed. If this can be done, it means that you will continue to have bowel movements normally, through your rectum and anus.",
"    </p>",
"    <p>",
"     In other cases, the colon cannot be reconnected during the initial surgery. This can happen if the surgeon feels there is a high risk of infection, or if the tissues are inflamed and need time to heal. If this occurs, the surgeon will sew the colon to an opening in the skin on the abdomen. The opening is called a colostomy (",
"     <a class=\"graphic graphic_figure graphicRef57774 \" href=\"UTD.htm?6/7/6256\">",
"      figure 2",
"     </a>",
"     ). You will wear a bag over the colostomy to collect bowel movements.",
"    </p>",
"    <p>",
"     The colostomy is usually temporary. The two ends of the colon can often be reconnected after a few months, sometimes after chemotherapy is completed. In other cases, you will need the colostomy permanently.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Life with a colostomy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Having a colostomy will change how your body looks, which can be hard to accept. However, with education and support, it is possible to lead an active life with a colostomy. A team effort, which includes the colorectal surgeon, oncologist, and an enterostomal therapy (ET) nurse, is valuable in learning about the surgery and also in the care and recovery required after the procedure. The United Ostomy Associations of America is also a good source of information and support (",
"     <a class=\"external\" href=\"file://www.uoaa.org/\">",
"      www.uoaa.org",
"     </a>",
"     ). (See",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/38/11875?source=see_link\">",
"      \"Patient information: Colostomy care (The Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Chemotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chemotherapy is a treatment given to slow or stop the growth of cancer cells. Even after a colon cancer has been completely removed with surgery, cancer cells can remain in the body, increasing the risk of the cancer coming back (called a relapse or recurrence). In some people, chemotherapy can eliminate these cancer cells and increase the chance of cure. This type of chemotherapy is called \"adjuvant\", which means that it is given after a curative surgery (at which time all the tumor was removed).",
"    </p>",
"    <p>",
"     Most treatments involve a combination of several chemotherapy drugs, which are given in a specific order on specific days. Most of the drugs are given into the vein (intravenous, IV), but sometimes a single drug will be recommended, which can be given in pill form. Regardless of the specific type of regimen, most adjuvant treatment regimens for colon cancer last about six months.",
"    </p>",
"    <p>",
"     Your healthcare provider can describe which chemotherapy drugs will be needed, how long treatment will last, and what side effects are expected from your treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Who needs chemotherapy?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chemotherapy is recommended for most people with stage III colon cancer (spread to the lymph nodes) and some people with stage II colon cancer (involvement of the whole thickness of the bowel wall but without involvement of the lymph nodes). Chemotherapy is not usually recommended for people with stage I colon cancer (cancer within the bowel wall but not all the way through it).",
"    </p>",
"    <p>",
"     Before you begin chemotherapy, it is important to discuss the potential risks and benefits of treatment with your doctor.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       In some cases, the benefits of chemotherapy (better chance of survival) clearly outweigh the possible risks (chemotherapy side effects like diarrhea, vomiting, hair loss, nerve damage, or more serious risks). Not everyone will have all of these side effects.",
"      </li>",
"      <li>",
"       In other cases, the small benefit of chemotherapy is not worth the risks.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     A Web-based tool called Adjuvant! Online can help you and your healthcare provider estimate the risk of cancer recurrence and the potential benefits of chemotherapy [",
"     <a class=\"abstract\" href=\"UTD.htm?6/0/6148/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      RECTAL CANCER TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The majority of rectal cancers are treated with a combination of surgery, radiation therapy, and chemotherapy; as with colon cancers, treatment is chosen based upon disease stage.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Stage I rectal cancer &mdash; Surgery alone may cure the cancer.",
"      </li>",
"      <li>",
"       Stage II and III &mdash; Chemotherapy and radiation therapy are typically recommended along with surgery; sometimes, the chemotherapy and radiation are given before surgery (referred to as neoadjuvant chemoradiotherapy), with additional chemotherapy given after surgery.",
"      </li>",
"      <li>",
"       Stage IV &mdash; Predominantly treated with chemotherapy, with or without surgery. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?39/22/40293?source=see_link\">",
"        \"Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Neoadjuvant chemoradiotherapy and radiotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;A combination of chemotherapy and radiation therapy may be recommended before surgery for patients with rectal cancer; this is called neoadjuvant chemoradiotherapy. This treatment can shrink the tumor before it is removed, reduces the risk that the cancer will come back, and may reduce the chances that you will need a permanent colostomy. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link\">",
"      \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The two most common ways to take chemotherapy during radiation therapy are:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A pump that fits into a pack you wear around your waist. The pump delivers the medicine (called 5-FU) into a port (an IV in your chest) continuously for about six weeks during radiation treatments.",
"      </li>",
"      <li>",
"       A daily dose of a pill called capecitabine. The pill is as effective as 5-FU given by pump and more convenient.",
"      </li>",
"      <li>",
"       Discuss all the potential risks and benefits of capecitabine with your doctor.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In some cases, a short course of radiation therapy alone (typically five daily treatments) may be recommended prior to surgery instead of combined chemotherapy and radiation. This approach is more popular outside of the United States.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgery removes the cancerous part of the rectum and the associated lymph nodes. Sometimes this will require that the anus be removed along with the rectum. If the anus and rectum have to be removed, the surgeon will sew the remaining intestine to an opening in the skin on the abdomen. The opening is called a colostomy. You will wear a bag over the opening to collect bowel movements. (See",
"     <a class=\"local\" href=\"#H7\">",
"      'Life with a colostomy'",
"     </a>",
"     above.)",
"    </p>",
"    <p>",
"     The type of surgery you have depends upon where your tumor is located and how far it has spread. Ask your surgeon to describe which surgery is right for you.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Treatment after surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Postoperative (adjuvant) therapy is typically recommended after surgery. The type of treatment you have after surgery depends upon the stage of your cancer, as well as the treatment you had before surgery. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4922?source=see_link\">",
"      \"Adjuvant therapy for resected rectal cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If your tumor is stage II or III, and you did not have chemotherapy and radiation therapy before surgery, you will probably have it after surgery. This is called adjuvant chemoradiotherapy (see",
"       <a class=\"local\" href=\"#H11\">",
"        'Neoadjuvant chemoradiotherapy and radiotherapy'",
"       </a>",
"       above).",
"      </li>",
"      <li>",
"       If you had chemoradiotherapy or radiation therapy alone before surgery, you will probably need approximately four months of chemotherapy alone (without further radiation therapy) after surgery.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Progress in treating cancer requires that better treatments be identified through clinical trials, which are conducted all over the world. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Ask for more information about clinical trials or read about clinical trials at:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials\">",
"        file://www.cancer.gov/clinicaltrials",
"       </a>",
"      </li>",
"      <li>",
"       <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"        file://clinicaltrials.gov/",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      FOLLOW-UP AFTER TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     After completing treatment for colorectal cancer, it is important to follow up with your healthcare team. You will need appointments on a regular basis for a few years to monitor for signs that the cancer has recurred. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28634?source=see_link\">",
"      \"Surveillance after colorectal cancer resection\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Your follow-up schedule may differ slightly, but most people will have the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A full colonoscopy is recommended before or after surgery to look for polyps or other cancers that were not seen previously. Colonoscopy is usually repeated one and four years after surgery, and every five years thereafter. If polyps or new cancers are found, this schedule may be adjusted.",
"      </li>",
"      <li>",
"       Visits with your healthcare provider are usually scheduled every three to four months for the first three years, every six months for two years, and then once per year. Most visits will include a discussion of how you are feeling and a physical examination. A blood test for a colorectal cancer tumor marker (CEA) may be done at each visit.",
"      </li>",
"      <li>",
"       A CT scan is usually recommended once per year for three years in people who have been treated for stage II or III colon cancer.",
"      </li>",
"      <li>",
"       For people who still have their anus after treatment for rectal cancer and who did not have radiation therapy, experts recommend a flexible proctosigmoidoscopy every six months for five years. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=see_link\">",
"        \"Patient information: Flexible sigmoidoscopy (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      COLORECTAL CANCER AND YOUR FAMILY",
"     </span>",
"    </p>",
"    <p>",
"     Having colon or rectal cancer means that your family may be at an increased risk of developing colorectal cancer. If you have one parent, brother, sister, or child with colorectal cancer or polyps at a young age (before the age of 60 years), or two relatives diagnosed at any age, you should begin screening for colon cancer earlier, typically at age 40, or 10 years younger than the earliest diagnosis in your family, whichever comes first. Colon cancer screening is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link\">",
"      \"Patient information: Colon and rectal cancer screening (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Certain genetic conditions increase the risk of colon cancer. The most common conditions include Lynch syndrome or hereditary nonpolyposis colon cancer (HNPCC), and familial adenomatous polyposis (FAP). If you have a strong family history of colon cancer (two or more close relatives), talk to your doctor about the need for genetic counseling and possible genetic testing.",
"    </p>",
"    <p>",
"     Although the idea of genetic testing can be frightening, the results of genetic tests can help determine whether you and your family need further treatment, testing, or closer surveillance.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our Web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10049626\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10049633\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/27/19890?source=see_link\">",
"      Patient information: Colon and rectal cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/34/25123?source=see_link\">",
"      Patient information: Colon and rectal cancer screening (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/38/11875?source=see_link\">",
"      Patient information: Colostomy care (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/9/38034?source=see_link\">",
"      Patient information: Colectomy (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10049648\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link\">",
"      Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/22/40293?source=see_link\">",
"      Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=see_link\">",
"      Patient information: Flexible sigmoidoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10049748\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=see_link\">",
"      Colorectal cancer: Epidemiology, risk factors, and protective factors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=see_link\">",
"      Clinical manifestations, diagnosis, and staging of colorectal cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30489?source=see_link\">",
"      Overview of the management of primary colon cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link\">",
"      Adjuvant therapy for resected stage III (node-positive) colon cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30586?source=see_link\">",
"      Adjuvant chemotherapy for resected stage II colon cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/51/11066?source=see_link\">",
"      Adjuvant therapy for resected colon cancer in elderly patients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38137?source=see_link\">",
"      Overview of surgical procedures for resectable primary rectal cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link\">",
"      Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4922?source=see_link\">",
"      Adjuvant therapy for resected rectal cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28634?source=see_link\">",
"      Surveillance after colorectal cancer resection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;1-800-4-CANCER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nci.nih.gov/\">",
"      www.nci.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Comprehensive Cancer Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nccn.com/\">",
"      www.nccn.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       \"Colon Cancer Can Run in the Family\". Berk T, Macrae, F (Eds). Available at",
"       <a class=\"external\" href=\"file://www.insight-group.org/links/CRCbook/\">",
"        www.insight-group.org/links/CRCbook/",
"       </a>",
"       .",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Cancer Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://cancer.about.com/forum\">",
"      file://cancer.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?6/0/6148/abstract/2-5\">",
"      2-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?6/0/6148?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     Adjuvant! Online program for colon cancer available online at www.adjuvantonline.com (Accessed on September 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6148/abstract/2\">",
"      Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001; 93:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6148/abstract/3\">",
"      Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 2007; 99:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6148/abstract/4\">",
"      Benson AB 3rd, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22:3408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6148/abstract/5\">",
"      Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev 2008; :CD005390.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f6_0_6148=[""].join("\n");
var outline_f6_0_6148=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           COLORECTAL CANCER OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           COLORECTAL CANCER SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           COLORECTAL CANCER DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           COLON CANCER TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           RECTAL CANCER TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           FOLLOW-UP AFTER TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           COLORECTAL CANCER AND YOUR FAMILY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/60/13250\" title=\"figure 1\">",
"           Diagram colon rectum PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/7/6256\" title=\"figure 2\">",
"           Colostomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f6_0_6149="Megestrol acetate: Pediatric drug information";
var content_f6_0_6149=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Megestrol acetate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"    see \"Megestrol acetate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/37/12885?source=see_link\">",
"    see \"Megestrol acetate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F192314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Megace&reg;;",
"     </li>",
"     <li>",
"      Megace&reg; ES",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F192315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Megestrol&reg;;",
"     </li>",
"     <li>",
"      Megace&reg;;",
"     </li>",
"     <li>",
"      Megace&reg; OS;",
"     </li>",
"     <li>",
"      Nu-Megestrol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1060125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Miscellaneous",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Progestin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1060118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"      see \"Megestrol acetate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Megace&reg; ES is not equivalent mg per mg with other megestrol formulations (625 mg Megace&reg; ES is equivalent to 800 mg megestrol tablets or suspension).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Appetite stimulant in cachexia: Titrate dosage to response; decrease dose if weight gain is excessive:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Limited data has been reported in cachectic children with cystic fibrosis, HIV, and solid tumors: Megestrol (tablets or 40 mg/mL suspension): 7.5-10 mg/kg/day in 1-4 divided doses; not to exceed 800 mg/day or 15 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Megestrol (tablets or 40 mg/mL suspension): 800 mg/day in 1-4 divided doses; titrate dose to response; doses between 400-800 mg/day have been clinically effective",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Megace&reg; ES: 625 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Breast carcinoma: Female Adults: Megestrol (tablets or 40 mg/mL suspension): 40 mg 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endometrial carcinoma: Female Adults: Megestrol (tablets or 40 mg/mL suspension): 40-320 mg/day in divided doses; not to exceed 800 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Uterine bleeding: Female Adults: Megestrol (tablets or 40 mg/mL suspension): 40 mg 2-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F192294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral, as acetate: 40 mg/mL (10 mL, 20 mL, 237 mL, 240 mL, 473 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Megace&reg;: 40 mg/mL (240 mL) [contains ethanol 0.06%, sodium benzoate; lemon-lime flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Megace&reg; ES: 125 mg/mL (150 mL) [contains ethanol 0.06%, sodium benzoate; lemon-lime flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as acetate: 20 mg, 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F192278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes Megace&reg; ES",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1060128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Shake oral suspension well before administering; administer without regard to food",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1060121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store tablets and oral suspension at room temperature; protect from heat",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1060127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Appetite stimulation and promotion of weight gain in cachexia (particularly in HIV patients) which is unresponsive to nutritional supplementation; palliative treatment of breast and endometrial carcinomas",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F192337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Megace&reg; may be confused with Reglan&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Megestrol may be confused with mesalamine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F192335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiomyopathy, chest pain, edema, heart failure, hypertension, palpitation, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal thinking, confusion, depression, fever, headache, hypoesthesia, insomnia, lethargy, malaise, mood changes, pain, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, pruritus, rash, vesiculobullous rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Adrenal insufficiency, amenorrhea, breakthrough bleeding, breast tenderness increased, cervical erosion and secretions (changes), Cushing's syndrome, diabetes, glucose intolerance, gynecomastia, hot flashes, HPA axis suppression, hypercalcemia, hyperglycemia, menstrual flow changes, spotting, vaginal bleeding pattern changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, flatulence, nausea, salivation increased, weight gain (not attributed to edema or fluid retention), xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, libido decreased, urinary frequency, urinary incontinence, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, hepatomegaly, hepatotoxicity, LDH increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Carpal tunnel syndrome, neuropathy, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Amblyopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Albuminuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, hyperpnea, pharyngitis, pneumonia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, herpes infection, infection, moniliasis, tumor flare",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Thromboembolic phenomena (including deep vein thrombosis, pulmonary embolism, thrombophlebitis)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1060132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to megestrol or any component; pregnancy (known or suspected); concomitant use with dofetilide",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1060117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with history of thromboembolic disease; use caution in patients with diabetes mellitus as increased insulin requirements have been reported in association with megestrol use",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1060116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . May cause fetal harm when administered during pregnancy; women of childbearing age should use appropriate contraceptive measures. May suppress HPA axis during chronic administration; acute adrenal insufficiency may occur with abrupt withdrawal after long-term use or with stress; withdrawal or discontinuation of megestrol should be done carefully. Consider providing exogenous glucocorticoids during periods of stress or severe infection.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Oral suspensions contain sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein-binding sites; avoid use of products containing sodium benzoate in neonates. Megestrol may inhibit the elimination of dofetilide resulting in increased dofetilide plasma concentrations and potential serious ventricular arrhythmias associated with QT interval prolongation; concomitant use with dofetilide is not recommended. Megestrol may reduce indinavir serum levels resulting in a need for increase in indinavir dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F192287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Progestins. Management: Progestin-containing contraceptives are not recommended; consider the use of alternative, nonhormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Megestrol may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2104108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A high fat meal significantly increases plasma levels; avoid herbs with progestogenic properties (eg, bloodroot, chasteberry, damiana, oregano, and yucca) as they may enhance the adverse/toxic effects of megestrol",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F192290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (tablet) / X (suspension) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4627707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were demonstrated in animal studies. Use during pregnancy is contraindicated (suspension).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1060124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for signs of thromboembolic phenomena and adrenal axis suppression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Appetite stimulation: Weight, caloric intake, basal cortisol level",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Antineoplastic: Tumor response",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1060115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A synthetic progestin with antiestrogenic properties which disrupt the estrogen receptor cycle. Megestrol interferes with the normal estrogen cycle and results in a lower LH titer. It may also have a direct effect on the endometrium. As an antineoplastic progestin, it is thought to act through an antileutenizing effect mediated via the pituitary. The exact mechanism for appetite stimulation has not been determined but is postulated to be due in part to a direct effect on the hypothalamus.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1060130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Antineoplastic: 2 months of continuous therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Weight gain: 2-4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1060131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: 10-120 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Suspension: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine (57% to 78%) and feces (8% to 30%) within 10 days",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1060123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/37/12885?source=see_link\">",
"      see \"Megestrol acetate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Follow dosage schedule and do not take more than prescribed. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs. May cause dry mouth. Report absent or altered menses, abdominal pain, vaginal itching, irritation, or discharge; report warmth, redness, or swelling of extremities, sudden onset of difficulty breathing, severe headache, or change in vision. May cause fetal harm particularly in the first 4 months of pregnancy; use appropriate contraception.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Eubanks V, Koppersmith N, Wooldridge N, et al, &ldquo;Effects of Megestrol Acetate on Weight Gain, Body Composition, and Pulmonary Function in Patients With Cystic Fibrosis,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2002, 140(4):439-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/0/6149/abstract-text/12006958 /pubmed\" id=\"12006958 \" target=\"_blank\">",
"        12006958",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nasr SZ, Hurwitz ME, Brown RW, et al, &ldquo;Treatment of Anorexia and Weight Loss With Megestrol Acetate in Patients With Cystic Fibrosis,&rdquo;",
"      <i>",
"       Pediatr Pulmonol",
"      </i>",
"      , 1999, 28(5):380-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/0/6149/abstract-text/10536070/pubmed\" id=\"10536070\" target=\"_blank\">",
"        10536070",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stockheim JA, Daaboul JJ, Yogev R, et al, &ldquo;Adrenal Suppression in Children With the Human Immunodeficiency Virus Treated With Megestrol Acetate,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1999, 134(3):368-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/0/6149/abstract-text/ 10064680 /pubmed\" id=\" 10064680 \" target=\"_blank\">",
"        10064680",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tchekmedyian NS, Hickman M, and Heber D, &ldquo;Treatment of Anorexia and Weight Loss With Megestrol Acetate in Patients With Cancer or Acquired Immunodeficiency Syndrome,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1991, 18(1 Suppl 2):35-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/0/6149/abstract-text/1992535 /pubmed\" id=\"1992535 \" target=\"_blank\">",
"        1992535",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12578 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-D4E9CFABE8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_0_6149=[""].join("\n");
var outline_f6_0_6149=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192314\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192315\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060125\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060118\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192294\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192278\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060128\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060121\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060127\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192337\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192335\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060132\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060117\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060116\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299657\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192287\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104108\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192290\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4627707\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060124\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060115\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060130\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060131\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060123\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12578\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12578|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=related_link\">",
"      Megestrol acetate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/37/12885?source=related_link\">",
"      Megestrol acetate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_0_6150="Management of bronchiectasis in children without cystic fibrosis";
var content_f6_0_6150=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of bronchiectasis in children without cystic fibrosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/0/6150/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/0/6150/contributors\">",
"     Khoulood Fakhoury, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/0/6150/contributors\">",
"     Adaobi Kanu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/0/6150/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/0/6150/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/0/6150/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/0/6150/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/0/6150/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchiectasis is a structural abnormality characterized by abnormal dilation and distortion of the bronchial tree, resulting in chronic obstructive lung disease. This condition is typically the end result of a variety of pathophysiologic processes that render the bronchial walls weakened, easily collapsible, chronically inflamed, and plugged with mucus secretions. Associated findings include atelectasis, emphysema, fibrosis, and hypertrophy of the bronchial vasculature.",
"   </p>",
"   <p>",
"    In developed nations, cystic fibrosis (CF) is the most common cause of bronchiectasis in children. The management of CF-related bronchiectasis is discussed in detail in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=see_link\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=see_link\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bronchiectasis can be caused by a variety of disease processes other than CF, most of which include some combination of bronchial obstruction and infection (",
"    <a class=\"graphic graphic_table graphicRef87712 \" href=\"UTD.htm?26/62/27630\">",
"     table 1",
"    </a>",
"    ). The types of disorders that cause bronchiectasis vary among populations and age groups. Infections and acquired causes of bronchiectasis are more common in adults and in developing nations, whereas congenital anomalies of the bronchi or immune system are more prominent in children and in industrialized nations.",
"   </p>",
"   <p>",
"    This topic review will describe the management and prevention of non-CF-related bronchiectasis in children. The causes, clinical manifestations, and diagnosis of non-CF-related bronchiectasis in children, and the treatment of bronchiectasis in adults are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16057?source=see_link\">",
"     \"Causes of bronchiectasis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44662?source=see_link\">",
"     \"Clinical manifestations and evaluation of bronchiectasis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=see_link\">",
"     \"Treatment of bronchiectasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MEDICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of bronchiectasis is aimed at treating the underlying cause (eg, removal of an airway foreign body, or treatment of aspiration or humoral immunodeficiency), improving mucociliary clearance, treating and preventing infection, and controlling inflammation.",
"   </p>",
"   <p>",
"    General treatment strategies for children with non-CF-related bronchiectasis are often extrapolated from studies in patients with CF or adults with bronchiectasis. This approach has some limitations, because the pathogenesis of bronchiectasis and pathogens seen in these populations can differ. Thus, optimal management depends upon the underlying cause of bronchiectasis and on individual patient characteristics, such as sputum cultures and the response to initial therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=see_link\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=see_link\">",
"     \"Treatment of bronchiectasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management approaches include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antibiotic therapy",
"     </li>",
"     <li>",
"      Chest physiotherapy",
"     </li>",
"     <li>",
"      Mucolytic agents and airway hydration",
"     </li>",
"     <li>",
"      Bronchodilators",
"     </li>",
"     <li>",
"      Anti-inflammatory drugs",
"     </li>",
"     <li>",
"      Immunization",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute respiratory exacerbations in patients with non-CF-related bronchiectasis are treated similarly to those in patients with CF. The choice of antibiotics is usually based upon sputum culture results; in young children who are unable to produce sputum, cultures can be obtained from a throat swab inserted deeply into the posterior pharynx to induce a cough. One study in children with newly diagnosed non-CF-related bronchiectasis in Australia suggests that Haemophilus influenzae is a common causative organism: at the time of diagnosis, H. influenzae was detected in 47 percent of specimens obtained by bronchoalveolar lavage (BAL), while P. aeruginosa was found in just 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6150/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For outpatient treatment of acute exacerbations, most patients are given oral antibiotics for 10 to 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6150/abstract/2\">",
"     2",
"    </a>",
"    ]. Intravenous antibiotics are reserved for severe exacerbations or exacerbations responding poorly to outpatient therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=see_link&amp;anchor=H3#H3\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\", section on 'Treatment of acute pulmonary exacerbations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inhaled aminoglycosides are administered chronically for patients with persistent Pseudomonas aeruginosa infection, similar to the approach for patients with CF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=see_link&amp;anchor=H17#H17\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\", section on 'Inhaled tobramycin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no data to guide the chronic use of antibiotics for children with non-CF-related bronchiectasis. In our practice, we use long-term antibiotics for patients with frequent acute exacerbations (eg, three or more exacerbations annually) or those with progressive deterioration of lung function. The antibiotic is tailored to sputum cultures and sensitivities, rather than chosen empirically, and administered for cycles of two weeks, alternating with two weeks without antibiotics. Although antibiotics may decrease certain microbial infections, the emergence of antibiotic-resistant organisms is a risk, as has been demonstrated in populations with CF [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6150/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Therefore, this method should be used judiciously for a defined time period, with clinical reevaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chest physiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchopulmonary hygiene is routinely performed to improve mucociliary clearance. A variety of techniques are used, including postural drainage and percussion, breathing and coughing techniques, airway oscillating devices, external percussion vests, and intrapulmonary percussive ventilation. Based upon studies in patients with cystic fibrosis, none of these techniques appears superior to others, although there are differences in convenience, compliance, and cost. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=see_link&amp;anchor=H9#H9\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Chest physiotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mucolytic agents and airway hydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data to guide the use of mucolytic agents in non-CF-related bronchiectasis.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/35/26163?source=see_link\">",
"     DNase",
"    </a>",
"    is recommended for treatment of many children with CF. However, one study in adults with idiopathic bronchiectasis reported potentially harmful effects of DNase (pulmozyme) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6150/abstract/5\">",
"     5",
"    </a>",
"    ]. As a result, DNase it is not routinely recommended for the management of non-CF-related bronchiectasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=see_link&amp;anchor=H5#H5\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Inhaled DNase I (dornase alfa)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=see_link\">",
"     \"Treatment of bronchiectasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Airway hydrating treatments (ie, hypertonic saline or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/60/43975?source=see_link\">",
"     mannitol",
"    </a>",
"    ) have not been sufficiently studied in adults or children with non-CF-related bronchiectasis to warrant their routine use [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6150/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bronchodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchodilator treatment may be appropriate in some children with bronchiectasis, but has not been studied rigorously. Bronchodilators relieve airway obstruction and may facilitate mucus clearance. A response to bronchodilators during pulmonary function testing can be used to identify patients who may benefit from bronchodilator therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"     azithromycin",
"    </a>",
"    are used for a subgroup of patients with CF-related bronchiectasis, but there is insufficient information to support their use in patients without CF.",
"   </p>",
"   <p>",
"    Chronic use of inhaled glucocorticoids is sometimes suggested for adult patients with bronchiectasis, but this practice is based upon limited evidence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=see_link\">",
"     \"Treatment of bronchiectasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to lack of studies in children, we do not suggest inhaled glucocorticoids as routine therapy in children with non-CF-related bronchiectasis. However, for patients with bronchiectasis and asthma, inhaled corticosteroids have greater clinical benefit, and this treatment should be used depending on asthma severity and control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with bronchiectasis, immunizations should be brought up to date and rigorously maintained. Maintenance of influenza and pneumococcal vaccinations are recommended. Live viral vaccines may not be appropriate for patients with some forms of immunodeficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H13#H13\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link&amp;anchor=H2#H2\">",
"     \"Standard immunizations for children and adolescents\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventing malnutrition is important in the management of bronchiectasis. In children with CF, malnutrition is associated with poor survival [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6150/abstract/7\">",
"     7",
"    </a>",
"    ], and aggressive nutritional rehabilitation improves lung function [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6150/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In patients with CF, some of the nutritional risks are caused by pancreatic insufficiency. It is also important to monitor and maintain nutritional status in patients with non-CF bronchiectasis, as for children with any chronic illness. Interventions to improve nutrition may include nutritional counseling to increase calories and nutrition quality, and liquid nutritional supplements taken by mouth or gastrostomy tube. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15754?source=see_link\">",
"     \"Cystic fibrosis: Nutritional issues\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemoptysis is uncommon in pediatric patients with bronchiectasis. Massive hemoptysis, variably defined as greater than 200 ml blood loss in a 24 hour period, or recurrent bleeding of more than 100 mL daily for several days [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6150/abstract/10\">",
"     10",
"    </a>",
"    ], represents a substantial risk and calls for prompt intervention. Resuscitative measures should be aimed at providing adequate oxygenation and restoring intravascular volume. Management is similar to that for patients with other causes of hemoptysis, and may include embolization or surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=see_link&amp;anchor=H34#H34\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Hemoptysis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/0/37896?source=see_link\">",
"     \"Hemoptysis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other rare complications of bronchiectasis include pneumothorax, empyema, and cor pulmonale [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6150/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is typically indicated in patients with localized bronchiectasis that results in severe symptoms, such as failure to thrive, recurrent infection, or severe hemoptysis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6150/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. Less commonly, surgery is used for patients with generalized bronchiectasis but localized and resectable complications, such as a nidus of infection or source of hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=see_link\">",
"     \"Treatment of bronchiectasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a 10-year followup of 84 pediatric patients undergoing resection for bronchiectasis, 39 percent had no significant symptoms or residual bronchiectasis, and 36 percent had marked reduction in symptoms but residual disease on radiographic study. Complications occurred in 11 percent of patients and included atelectasis, pneumothorax, chylothorax, bronchopulmonary fistula, and respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6150/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lung transplantation is a procedure of last resort for patients with bronchiectasis. Most long-term studies have been done in patients with CF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of bronchiectasis in adults\", section on 'Lung transplantation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=see_link&amp;anchor=H26#H26\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Lung transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following measures prevent or reduce the severity of respiratory infections, and thereby reduce the risk for developing bronchiectasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preventing tobacco smoke exposure (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41895?source=see_link\">",
"       \"Control of secondhand smoke exposure\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ensuring completion of vaccination series, particularly the pneumococcal and influenza vaccines (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link&amp;anchor=H2#H2\">",
"       \"Standard immunizations for children and adolescents\", section on 'Overview'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Aggressively treating respiratory infections, including suspected persistent bacterial bronchitis (PBB); identification and treatment of the underlying cause for recurrent pneumonias or other respiratory infections, including retained foreign bodies (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link\">",
"       \"Approach to the child with recurrent infections\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/57/40850?source=see_link\">",
"       \"Patient information: Bronchiectasis in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bronchiectasis is characterized by abnormal dilation and distortion of the bronchial tree, resulting in chronic obstructive lung disease. This condition is the end result of a variety of pathophysiologic processes, usually a combination of infection and impaired airway drainage or obstruction. Important causes of bronchiectasis in children include cystic fibrosis, chronic aspiration, infection (with or without underlying immunodeficiency), foreign body aspiration, and congenital pulmonary defects (",
"      <a class=\"graphic graphic_table graphicRef87712 \" href=\"UTD.htm?26/62/27630\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16057?source=see_link\">",
"       \"Causes of bronchiectasis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Management strategies for bronchiectasis in children depend on the underlying cause of bronchiectasis and individual patient characteristics. These approaches are similar to those used for adult patients with bronchiectasis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Medical treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=see_link\">",
"       \"Treatment of bronchiectasis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For most pediatric patients with non-CF-related bronchiectasis, we suggest systemic antibiotics to treat acute exacerbations (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We also suggest routine chest physiotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antibiotic therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Chest physiotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For those with persistent Pseudomonas aeruginosa infection, we suggest chronic treatment with inhaled aminoglycosides (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with frequent acute exacerbations or progressive deterioration of lung function, we suggest treatment with long-term antibiotics (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The antibiotics are tailored to sputum cultures and sensitivities, rather than chosen empirically, and the patient is reevaluated periodically (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Antibiotic therapy'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      For children with non-CF-related bronchiectasis we suggest NOT treating with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/35/26163?source=see_link\">",
"       DNase",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Although DNase is recommended for children with CF, it is not effective in adults with non-CF-related bronchiectasis, and may even be harmful. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Mucolytic agents and airway hydration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6150/abstract/1\">",
"      Kapur N, Grimwood K, Masters IB, et al. Lower airway microbiology and cellularity in children with newly diagnosed non-CF bronchiectasis. Pediatr Pulmonol 2012; 47:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6150/abstract/2\">",
"      Sethi GR, Batra V. Bronchiectasis: causes and management. Indian J Pediatr 2000; 67:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6150/abstract/3\">",
"      Smyth AR, Walters S. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2012; 12:CD001912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6150/abstract/4\">",
"      Hill RL, Kearns AM, Nash J, et al. Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients. J Antimicrob Chemother 2010; 65:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6150/abstract/5\">",
"      O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998; 113:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6150/abstract/6\">",
"      Redding GJ. Bronchiectasis in children. Pediatr Clin North Am 2009; 56:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6150/abstract/7\">",
"      Sharma R, Florea VG, Bolger AP, et al. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax 2001; 56:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6150/abstract/8\">",
"      Shepherd RW, Holt TL, Thomas BJ, et al. Nutritional rehabilitation in cystic fibrosis: controlled studies of effects on nutritional growth retardation, body protein turnover, and course of pulmonary disease. J Pediatr 1986; 109:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6150/abstract/9\">",
"      Marchand V, Baker SS, Stark TJ, Baker RD. Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2000; 31:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6150/abstract/10\">",
"      Jean-Baptiste E. Clinical assessment and management of massive hemoptysis. Crit Care Med 2000; 28:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6150/abstract/11\">",
"      Lewiston NJ. Bronchiectasis in childhood. Pediatr Clin North Am 1984; 31:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6150/abstract/12\">",
"      Wilson JF, Decker AM. The surgical management of childhood bronchiectasis. A review of 96 consecutive pulmonary resections in children with nontuberculous bronchiectasis. Ann Surg 1982; 195:354.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6355 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-926874B457-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_0_6150=[""].join("\n");
var outline_f6_0_6150=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MEDICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chest physiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mucolytic agents and airway hydration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bronchodilators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Immunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6355\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6355|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/62/27630\" title=\"table 1\">",
"      Causes and evaluation of bronchiectasis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16057?source=related_link\">",
"      Causes of bronchiectasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44662?source=related_link\">",
"      Clinical manifestations and evaluation of bronchiectasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41895?source=related_link\">",
"      Control of secondhand smoke exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=related_link\">",
"      Cystic fibrosis: Antibiotic therapy for lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15754?source=related_link\">",
"      Cystic fibrosis: Nutritional issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=related_link\">",
"      Cystic fibrosis: Overview of the treatment of lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/0/37896?source=related_link\">",
"      Hemoptysis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/57/40850?source=related_link\">",
"      Patient information: Bronchiectasis in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=related_link\">",
"      Treatment of bronchiectasis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_0_6151="Chlorpropamide: Drug information";
var content_f6_0_6151=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chlorpropamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/5/40020?source=see_link\">",
"    see \"Chlorpropamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F150611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Chlorpropamide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F150648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Sulfonylurea",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F150615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Type 2 diabetes: Oral: The dosage of chlorpropamide is variable and should be individualized based upon the patient's response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Initial dose:",
"     </i>",
"     250 mg daily in mild-to-moderate diabetes in middle-aged, stable diabetic patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Titration:",
"     </i>",
"     After 5-7 days of initiation, subsequent daily dosages may be increased or decreased by 50-125 mg at 3- to 5-day intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Maintenance dose:",
"     </i>",
"     100-250 mg daily; severe patients with diabetes may require 500 mg daily; avoid doses &gt;750 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F150616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Reduce initial dose to 100-125 mg/day in older patients; after 5-7 days of initiation, subsequent daily dosages may be increased or decreased by 50-125 mg at 3- to 5-day intervals (slower upward titration may be appropriate in older patients)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F150617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     No specific dosage adjustment provided in manufacturer&rsquo;s labeling; conservative initial and maintenance doses are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Alternate recommendations (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: Reduce dose by 50%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Avoid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Avoid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis: Avoid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Avoid use.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F150618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     No specific dosage adjustment provided in manufacturer&rsquo;s labeling; conservative initial and maintenance doses are recommended in patients with liver impairment since chlorpropamide undergoes extensive hepatic metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F150589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 100 mg, 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F150574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9460444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer once daily with breakfast. Daily dose may be divided to reduce GI upset. Patients that are NPO or require decreased caloric intake may need doses held to avoid hypoglycemia.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F150592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of blood sugar in type 2 diabetes mellitus (noninsulin dependent, NIDDM) as an adjunct to diet and exercise to lower blood glucose",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F150644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Central (neurogenic) diabetes insipidus",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F150653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ChlorproPAMIDE may be confused with chlorproMAZINE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Diabinese may be confused with DiaBeta&reg;, Diamox&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F150646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus (&lt;3%), maculopapular eruptions (&le;1%), urticaria (&le;1%), erythema multiforme, exfoliative dermatitis,  photosensitivity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Disulfiram-like reactions, hypoglycemia, SIADH",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea (&lt;5%), anorexia (&lt;2%), diarrhea (&lt;2%), hunger (&lt;2%), vomiting (&lt;2%), proctocolitis (&lt;1%), weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, eosinophilia, hemolytic anemia, leukopenia, pancytopenia, porphyria cutanea tarda, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, hepatic porphyria, hepatitis, liver failure",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F150595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chlorpropamide or any component of the formulation; type 1 diabetes mellitus (insulin dependent, IDDM); diabetic ketoacidosis (with or without coma)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F150578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular mortality: Product labeling states oral hypoglycemic drugs may be associated with an increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. Data to support this association are limited, and several studies, including a large prospective trial (UKPDS, 1998) have not supported an association.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when ethanol is ingested, or when more than one glucose-lowering drug is used. It is also more likely in elderly patients, malnourished patients and in patients with impaired renal or hepatic function; use with caution. Autonomic neuropathy, advanced age, and concomitant use of beta-blockers or other sympatholytic agents may impair the patient&rsquo;s ability to recognize the signs and symptoms of hypoglycemia; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use with caution in patients with sulfonylurea or sulfonamide allergy; a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Patients with G6PD deficiency may be at an increased risk of sulfonylurea-induced hemolytic anemia; however, cases have also been described in patients without G6PD deficiency during postmarketing surveillance. Use with caution and consider a nonsulfonylurea alternative in patients with G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stress-related states: It may be necessary to discontinue therapy and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use in this age group due to prolonged half-life/hypoglycemia and risk of causing SIADH (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;  Long half-life: Patients should be properly instructed in the early detection and treatment of hypoglycemia; long half-life may complicate recovery from excess effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary failure: Loss of efficacy may be observed following prolonged use as a result of the progression of type 2 diabetes mellitus which results in continued beta cell destruction. In patients who were previously responding to sulfonylurea therapy, consider additional factors which may be contributing to decreased efficacy (eg, inappropriate dose, nonadherence to diet and exercise regimen). If no contributing factors can be identified, consider discontinuing use of the sulfonylurea due to secondary failure of treatment.  Additional antidiabetic therapy (eg, insulin) will be required.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F150643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F150583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): Sulfonylureas may enhance the adverse/toxic effect of Alcohol (Ethyl). A flushing reaction may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May increase the serum concentration of ChlorproPAMIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May decrease the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclic Antidepressants: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GLP-1 Agonists: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose reductions when used in combination with GLP-1 agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the hypoglycemic effect of Sulfonylureas. This appears to be particularly concerning early in the course of combination therapy. Quinolone Antibiotics may diminish the hypoglycemic effect of Sulfonylureas. With longer-term combination, there is a greater risk of hyperglycemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranitidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Sulfonylureas may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F150607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Avoid ethanol (possible disulfiram-like reaction).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Herbs with hypoglycemic properties may enhance the hypoglycemic effect of chlorpropamide. This includes alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng (American), gymnema, marshmallow, stinging nettle",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F150584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F150598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted; therefore, the manufacturer classifies chlorpropamide as pregnancy category C. Chlorpropamide crosses the placenta and measurable serum concentrations can be found in infants exposed",
"     <i>",
"      in utero",
"     </i>",
"     . Teratogenic effects have been associated with chlorpropamide use in some studies; however, it is unknown if this is related to the medication or uncontrolled diabetes. Nonteratogenic adverse effects (eg, severe neonatal hypoglycemia, increased perinatal mortality) have also been associated with maternal chlorpropamide use. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is above the normal range. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the mother and the fetus. Until additional safety and efficacy data are obtained, the use of oral agents is generally not recommended as routine management of GDM or type 2 diabetes mellitus during pregnancy. The manufacturer recommends if chlorpropamide is used during pregnancy, it should be discontinued at least 1 month before the expected delivery date. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F150619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5651827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chlorpropamide is found in breast milk. Breast-feeding is not recommended by the manufacturer. Potentially, hypoglycemia may occur in a nursing infant exposed to a sulfonylurea via breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F150599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause GI upset; take with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F150597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (ChlorproPAMIDE Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $58.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $122.90",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F150587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood glucose, Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     ; monitor for signs and symptoms of hypoglycemia (fatigue, sweating, numbness of extremities)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F150590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F150600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Abemide (JP, TW);",
"     </li>",
"     <li>",
"      Adiaben (HR);",
"     </li>",
"     <li>",
"      Anti-D (SG);",
"     </li>",
"     <li>",
"      Arodoc C (JP);",
"     </li>",
"     <li>",
"      Bioglumin (ES);",
"     </li>",
"     <li>",
"      Chlormide (JP);",
"     </li>",
"     <li>",
"      Chlorpropamid (PL);",
"     </li>",
"     <li>",
"      Copamide (IN);",
"     </li>",
"     <li>",
"      Dabinese (VE);",
"     </li>",
"     <li>",
"      Diabemide (BF, BJ, CI, ET, GH, GM, GN, IT, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Diabenese (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CO, CR, CY, DO, EG, ET, GB, GH, GM, GN, GR, GT, GY, HN, IL, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, NE, NG, NI, NL, OM, PA, PR, PT, QA, SA, SC, SD, SL, SN, SR, SV, SY, TN, TT, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Diabet (ES);",
"     </li>",
"     <li>",
"      Diabezin (TW);",
"     </li>",
"     <li>",
"      Diabines (SE);",
"     </li>",
"     <li>",
"      Diabinese (AR, AU, BE, BR, CH, CN, EC, ES, HK, HR, ID, IE, KP, LU, NO, PE, PH, PK, PL, TH, TR, UY);",
"     </li>",
"     <li>",
"      Diabitex (BB, BM, BS, BZ, GY, JM, NL, SR, TT, ZA);",
"     </li>",
"     <li>",
"      Dibecon (TH);",
"     </li>",
"     <li>",
"      Glicoben (BR);",
"     </li>",
"     <li>",
"      Glycemin (TH);",
"     </li>",
"     <li>",
"      Hypomide (ZA);",
"     </li>",
"     <li>",
"      Insogen (MX);",
"     </li>",
"     <li>",
"      Litangen (TW);",
"     </li>",
"     <li>",
"      Meldian (HR);",
"     </li>",
"     <li>",
"      Mellitos C (JP);",
"     </li>",
"     <li>",
"      Propamide (MY, SG);",
"     </li>",
"     <li>",
"      Trane (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F150577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates insulin release from the pancreatic beta cells; reduces glucose output from the liver; insulin sensitivity is increased at peripheral target sites",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F150594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.13-0.23 L/kg (Arrigoni, 1987)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic (~80%), primarily via CYP2C9; forms metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~36 hours; prolonged in elderly or with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     End-stage renal disease: 50-200 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (unchanged drug and as hydroxylated or hydrolyzed metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/0/6151/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/0/6151/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 111.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arrigoni L, Fundak G, Horn J, et al, &ldquo;Chlorpropamide Pharmacokinetics in Young Healthy Adults and Older Diabetic Patients,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1987, 6(2):162-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/0/6151/abstract-text/3665370/pubmed\" id=\"3665370\" target=\"_blank\">",
"        3665370",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;A Study of the Effects of Hypoglycemia Agents on Vascular Complications in Patients With Adult-onset Diabetes. VI. Supplementary Report on Nonfatal Events in Patients Treated With Tolbutamide. The University Group Diabetes Program,&rdquo;",
"      <i>",
"       Diabetes",
"      </i>",
"      , 1976, 25(12):1129-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/0/6151/abstract-text/992232/pubmed\" id=\"992232\" target=\"_blank\">",
"        992232",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, \"Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,\"",
"      <i>",
"       Can J Diabetes",
"      </i>",
"      , 20078, 32(suppl 1):1-201.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Effect of Intensive Blood-Glucose Control With Metformin on Complications in Overweight Patients With Type 2 Diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1998, 352(9131):854-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/0/6151/abstract-text/9742977/pubmed\" id=\"9742977\" target=\"_blank\">",
"        9742977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garratt KN, Brady PA, Hassinger NL, et al, &ldquo;Sulfonylurea Drugs Increase Early Mortality in Patients With Diabetes Mellitus After Direct Angioplasty for Acute Myocardial Infarction,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 33(1):119-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/0/6151/abstract-text/9935017/pubmed\" id=\"9935017\" target=\"_blank\">",
"        9935017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirkman M, Briscoe VJ, Clark N, et al, \"Diabetes in Older Adults: A Consensus Report,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012; doi: 10.1111/jgs.12035.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/0/6151/abstract-text/23106132/pubmed\" id=\"23106132\" target=\"_blank\">",
"        23106132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klamann A, Sarfert P, Launhardt V, et al, &ldquo;Myocardial Infarction in Diabetic vs Nondiabetic Subjects. Survival and Infarct Size Following Therapy With Sulfonylureas (Glibenclamide),",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 2000, 21(3):220-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meinert CL, Knatterud GL, Prout TE, et al, &ldquo;A Study of the Effects of Hypoglycemic Agents on Vascular Complications in Patients With Adult-Onset Diabetes. II. Mortality Results,&rdquo;",
"      <i>",
"       Diabetes",
"      </i>",
"      , 1970, 19:789-830.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/0/6151/abstract-text/4926376/pubmed\" id=\"4926376\" target=\"_blank\">",
"        4926376",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Keefe JH, Blackstone EH, Sergeant P, et al, &ldquo;The Optimal Mode of Coronary Revascularization for Diabetics. A Risk-Adjusted Long-Term Study Comparing Coronary Angioplasty and Coronary Bypass Surgery,&rdquo;",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 1998, 19(11):1696-703.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/0/6151/abstract-text/9857923/pubmed\" id=\"9857923\" target=\"_blank\">",
"        9857923",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/0/6151/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      UK Prospective Diabetes Study (UKPDS) Group, &ldquo;Intensive Blood-Glucose Control With Sulphonylureas or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes (UKPDS 33),&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1998, 352(9131):837-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/0/6151/abstract-text/9742976/pubmed\" id=\"9742976\" target=\"_blank\">",
"        9742976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Verbalis JG, &ldquo;Diabetes Insipidus,&rdquo;",
"      <i>",
"       Rev Endocr Metab Disord",
"      </i>",
"      , 2003, 4(2):177-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/0/6151/abstract-text/12766546/pubmed\" id=\"12766546\" target=\"_blank\">",
"        12766546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9253 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-4D580CFE0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_0_6151=[""].join("\n");
var outline_f6_0_6151=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150611\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150648\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150615\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150616\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150617\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150618\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150589\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150574\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9460444\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150592\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150644\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150653\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150646\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150595\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150578\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150643\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150583\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150607\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150584\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150598\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150619\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5651827\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150599\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150597\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150587\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150590\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150600\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150577\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150594\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9253\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9253|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/5/40020?source=related_link\">",
"      Chlorpropamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_0_6152="Principles of management of enteric fistulas";
var content_f6_0_6152=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Principles of management of enteric fistulas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/0/6152/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/0/6152/contributors\">",
"     William Schecter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/0/6152/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/0/6152/contributors\">",
"     David I Soybel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/0/6152/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/0/6152/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/0/6152/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H18524881\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A fistula is an abnormal communication between two epithelialized surfaces. An enterocutaneous fistula (ECF) is a communication between the bowel lumen and the skin. An exposed or enteroatmospheric fistula refers to drainage of intestinal contents from an open abdomen with no overlying soft tissue.",
"   </p>",
"   <p>",
"    Enteric fistulas represent difficult clinical complications, with significant morbidity and mortality. This topic review will focus on the management of external gastrointestinal enterocutaneous and enteroatmospheric fistulas. Internal fistulas and other types of fistulas are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32951?source=see_link\">",
"     \"Rectovaginal, anovaginal, and colovesical fistulas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44792?source=see_link\">",
"     \"Urogenital tract fistulas in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26246?source=see_link\">",
"     \"Perianal abscess: Clinical manifestations, diagnosis, treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42819?source=see_link\">",
"     \"Acute diverticulitis complicated by fistula formation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28903?source=see_link\">",
"     \"Clinical features, diagnosis, and prevention of pancreatic fistulas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1480967\">",
"    <span class=\"h1\">",
"     PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common presentation of an enteric fistula is in a postoperative patient with abdominal distension and tenderness, a low grade fever, and failure to recover normally from abdominal surgery. A wound infection is recognized and drained 7 to 10 days after surgery, followed by the appearance of enteric contents in the surgical wound [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/1\">",
"     1",
"    </a>",
"    ]. Preoperative factors that increase the likelihood of the development of a fistula include malnutrition, infection, and emergency procedures. Spontaneous fistula formation is most common in inflammatory bowel disease, malignancy, or following radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18116253\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF ENTERIC FISTULAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteric fistulas are classified as enterocutaneous or enteroatmospheric (exposed) fistulas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H322734\">",
"    <span class=\"h2\">",
"     Enterocutaneous fistulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enterocutaneous fistulas are classified with regard to anatomy, etiology, physiology [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The anatomic classification of enteric fistulas is based upon the segment of bowel from which it originates (ie, gastrocutaneous, colocutaneous).",
"     </li>",
"     <li>",
"      The etiologic classification is based upon the underlying disease process (ie, postoperative, trauma, foreign body, Crohn&rsquo;s disease, diverticulitis, tuberculosis, malignancy) (",
"      <a class=\"graphic graphic_table graphicRef76953 \" href=\"UTD.htm?24/44/25291\">",
"       table 1",
"      </a>",
"      ). Most fistulas are the result of bowel injury during surgery, a leak from a bowel anastomosis, or erosion of mesh into adjacent bowel [",
"      <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/1\">",
"       1",
"      </a>",
"      ]. Approximately 20 to 40 percent of all enterocutaneous fistulas result from Crohn&rsquo;s disease [",
"      <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link&amp;anchor=H12689057#H12689057\">",
"       \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\", section on 'Fistulas'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The physiologic classification is based on the volume of fistula output.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A low output fistula drains less than 200",
"      <span class=\"nowrap\">",
"       mL/day.",
"      </span>",
"     </li>",
"     <li>",
"      A moderate output fistula drains between 200 and 500",
"      <span class=\"nowrap\">",
"       mL/day.",
"      </span>",
"     </li>",
"     <li>",
"      A high output fistula drains more than 500",
"      <span class=\"nowrap\">",
"       mL/day.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H322742\">",
"    <span class=\"h2\">",
"     Enteroatmospheric (exposed) fistulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteroatmospheric or exposed fistulas occur in the midst of an open abdomen with no overlying soft tissue (",
"    <a class=\"graphic graphic_picture graphicRef58058 \" href=\"UTD.htm?14/50/15140\">",
"     picture 1",
"    </a>",
"    ). These fistulas occur when the abdomen is left open after trauma or emergency surgery and are classified on the basis of the surrounding abdominal wound [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A deep exposed fistula is characterized by uncontrolled infection and drains intestinal content directly into the peritoneal cavity, causing peritonitis.",
"     </li>",
"     <li>",
"      A superficial exposed fistula drains atop the granulating wound of a frozen abdomen (densely adherent intestines and other abdominal organs, also called fused visceral block) with an obliterated peritoneal cavity, and primarily represents a wound management and nutritional support problem.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18524895\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF ENTEROCUTANEOUS FISTULAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment of an enterocutaneous fistula focuses on the correction of fluid and electrolyte imbalance, abscess drainage and treatment of infection, correction of malnutrition, and meticulous fistula control and skin care (",
"    <a class=\"graphic graphic_table graphicRef57027 \" href=\"UTD.htm?23/19/23868\">",
"     table 2",
"    </a>",
"    ). Approximately one-third of enterocutaneous fistulas will heal spontaneously with these measures within five to six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who do not respond to conservative measures should be referred to a center capable of providing complex multidisciplinary care [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/8\">",
"     8",
"    </a>",
"    ]. Treatment of enteric fistulas in specialized centers of excellence improves outcomes and decreases the mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/4,9,10\">",
"     4,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spontaneous fistula closure rates vary depending upon the cause and volume of the fistula and the presence of well-vascularized soft tissue over the fistula (",
"    <a class=\"graphic graphic_table graphicRef76451 \" href=\"UTD.htm?29/48/30476\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/11-21\">",
"     11-21",
"    </a>",
"    ]. Distal obstruction, a short epithelialized fistula tract, infection, and malignancy are barriers to spontaneous closure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H320290\">",
"    <span class=\"h2\">",
"     Fluid and electrolyte imbalance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive correction of hypovolemia should occur in the first few hours of treatment. Measurement of electrolytes in the fistula fluid helps to guide proper replacement. Hypokalemia is the most common electrolyte abnormality. Ongoing fluid losses from high output upper gastrointestinal fistulas should be replaced with isotonic saline and potassium supplementation with serial measurements of serum electrolytes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link\">",
"     \"Clinical manifestations and treatment of hypokalemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Duodenal or pancreatic fistulas may require bicarbonate replacement because of the development of metabolic acidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23878?source=see_link\">",
"     \"Treatment of pancreatic fistulas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link&amp;anchor=H15#H15\">",
"     \"Approach to the adult with metabolic acidosis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H320484\">",
"    <span class=\"h2\">",
"     Abscess drainage and treatment of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enterocutaneous fistulas are often associated with intra-abdominal infection, which can present as a contained abscess or peritonitis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peritonitis is a surgical emergency requiring laparotomy. Laparotomy for source control most often requires exteriorization of the fistula or proximal diversion. Rarely, an early fistula can be resected or closed primarily.",
"     </li>",
"     <li>",
"      Contained abscesses are amenable to percutaneous computed tomography (CT) or ultrasound (US) guided drainage [",
"      <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/23\">",
"       23",
"      </a>",
"      ]. A CT scan with oral contrast is useful to demonstrate the anatomy of the fistula, associated intra-abdominal abscesses, and areas of distal obstruction as well as directing percutaneous drainage procedures. Percutaneous abscess drainage with radiologic guidance is often possible to control and treat infection associated with fistula formation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Drainage is usually performed through the anterior abdominal wall. However, abscesses deep in the pelvis or obscured by other organs may be accessed with a variety of approaches, including transgastric, transrectal, transvaginal, and transgluteal [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/24\">",
"     24",
"    </a>",
"    ]. The drainage catheter is usually left in place until drainage is less than 10 mL in 24 hours; this may take as long as 30 days. Catheter fistulograms during this period can show persistent communication between fistula and bowel, and permit assessment of resolution of the abscess cavity. Surgical intervention is needed if improvement does not occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H320386\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a fistula should not be allowed to eat (NPO [nil per os]) during the initial stage of treatment. Nutritional support should be initiated slowly after correction of fluid, electrolyte, and vitamin deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Baseline requirements for carbohydrates, fat, and protein increase with high output fistulas from 20",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day of carbohydrates and fat and 0.8",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day of protein to 30",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    and 1.5 to 2.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day, respectively. Enteral feedings are preferable because of the positive effects on immunologic and hormonal gut function, but are often impractical because of feeding intolerance, lack of access to the gastrointestinal tract, or high output fistula losses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1480975\">",
"    <span class=\"h2\">",
"     Fistulogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of sepsis, a fistulogram should be performed by the radiologist and surgeon working together to determine the origin of the fistula, document intestinal continuity, and ascertain the presence of distal obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/1,23,28\">",
"     1,23,28",
"    </a>",
"    ]. A fistulogram is performed by injecting a water soluble contrast agent into the cutaneous opening. Following complete visualization of the tract, angiographic catheters and guide wires can be used under fluoroscopic guidance to outline any associated pockets or cavities [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/23\">",
"     23",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18524911\">",
"    <span class=\"h2\">",
"     Fistula control and skin care",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sump or pouch should be placed around the fistula. The adjacent skin must be protected with DuoDERM or other skin protectants. Skin protection creams and effluent collection bags must be tailored to the unique characteristics of each fistula, but the principles are similar to those used in the care of a colostomy or ileostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/29\">",
"     29",
"    </a>",
"    ]. The assistance of a skilled enterostomal therapist is helpful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2218?source=see_link\">",
"     \"Management of patients with a colostomy or ileostomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vacuum-assisted wound management can be used to control the intestinal spillage and may accelerate fistula closure by promoting wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. A study of vacuum-assisted wound management of 179 fistulas in 91 patients reported spontaneous closure in 40 percent within 90 days and 85 percent of the remaining fistulas closed following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/32\">",
"     32",
"    </a>",
"    ]. The mortality rate was 16 percent (",
"    <a class=\"graphic graphic_picture graphicRef63582 \" href=\"UTD.htm?32/15/33016\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=see_link\">",
"     \"Negative pressure wound therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fistula output can be reduced with somatostatin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , a somatostatin analogue. However, these drugs are costly and there is no evidence that they improve the rate of fistula closure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18524932\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have failed five to six weeks of nonoperative management will likely need surgery. However, surgery should not be undertaken for another few months to avoid bowel injury. The presence of an enterocutaneous fistula is usually associated with a phase of dense adhesions, termed &ldquo;obliterative peritonitis,&rdquo; making early surgery a hazardous undertaking [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/15,35\">",
"     15,35",
"    </a>",
"    ]. Obliterative peritonitis may resolve as early as six weeks in a closed abdomen, but may persist for 6 to 12 months in a patient with an open abdomen.",
"   </p>",
"   <p>",
"    The goal of surgery for an enterocutaneous fistula is to reestablish the continuity of the intestinal tract and to achieve a tension-free closure of the abdomen with well-vascularized soft tissue. Before consideration of definitive repair of fistulas which fail to close spontaneously, patients should be nutritionally replete, free of infection, and have supple soft tissues adjacent to the fistula.",
"   </p>",
"   <p>",
"    Resection of a chronic enterocutaneous fistula requires careful planning, meticulous dissection to mobilize the entire intestinal tract, and resection of the segment of bowel that is the source of the fistula. Closure of large abdominal wall defects may require more complicated hernia repair techniques. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43801?source=see_link\">",
"     \"Overview of abdominal hernias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/34/32294?source=see_link\">",
"     \"Principles of component separation technique for complex abdominal wall defects and hernias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incision should be chosen to try and avoid adhesions and bowel loops adherent to the abdominal wall at the site of prior incisions. A new incision or extension of the previous incision in a cephalad direction will allow entry into a \"virgin\" area. Adhesions are then lysed and taken down from the abdominal wall.",
"   </p>",
"   <p>",
"    The adhesions are often dense and the dissection should be slow and careful. Expert surgeons recommend working laterally and delivering the bowel and adhesions from the side where they are more likely to be free [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/1\">",
"     1",
"    </a>",
"    ]. Several techniques can be used to facilitate the dissection of dense adhesions. We inject isotonic saline into areas of dense adhesions. Others have reported placing an antibiotic soaked (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/10/40102?source=see_link\">",
"     kanamycin",
"    </a>",
"    ) sponge on areas of difficult adhesions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/1\">",
"     1",
"    </a>",
"    ]. Both methods help to reveal the plane between bowel loops.",
"   </p>",
"   <p>",
"    After resection of the affected bowel, a gastrostomy tube and feeding jejunostomy should be placed. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1481392\">",
"    <span class=\"h3\">",
"     Duodenal fistulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duodenal fistulas are managed differently from other enteric fistulas [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/2\">",
"     2",
"    </a>",
"    ]. Duodenal fistulas result from sphincterotomies, perforated duodenal ulcers, or gastrectomy. The majority of duodenal fistulas will heal with nonoperative management. Those that fail to heal are best treated with gastrojejunostomy rather than resection, which would require pancreaticoduodenectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18524939\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF ENTEROATMOSPHERIC FISTULAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteroatmospheric (exposed) fistulas will",
"    <strong>",
"     not",
"    </strong>",
"    heal spontaneously because of the absence of overlying soft tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18524947\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteroatmospheric fistulas can be prevented by coverage of exposed bowel with omentum or other biologic dressings during open abdomen management [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Negative pressure wound sponges and gauze dressings should",
"    <strong>",
"     not",
"    </strong>",
"    be applied directly to exposed bowel, particularly if there is an exposed suture line. Access to the wound should be limited to one or two highly experienced providers to reduce the risk of iatrogenic bowel injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H322894\">",
"    <span class=\"h2\">",
"     Superficial enteroatmospheric fistulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;A superficial enteroatmospheric fistula results in spillage of intestinal contents onto the granulation tissue covering a frozen abdomen (fused visceral block). Direct suture closure of small &ldquo;bud&rdquo; fistulas is sometimes possible. In other cases autogenous skin grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/38\">",
"     38",
"    </a>",
"    ] or acellular lumen dermal matrix [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/39\">",
"     39",
"    </a>",
"    ] will be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H322677\">",
"    <span class=\"h2\">",
"     Deep enteroatmospheric fistulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;While a superficial enteroatmospheric fistula is primarily a wound management problem, a deep fistula typically results in peritonitis and critical illness. Referral to a center capable of providing complex multidisciplinary care is prudent in these difficult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H322712\">",
"    <span class=\"h3\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional support is essential to reverse the catabolic effects of a deep exposed fistula. The ongoing peritonitis, large open abdominal wound, and protein losses from the gastrointestinal tract often require a combination of enteral and parenteral nutrition to deliver sufficient nutrients and replace essential elements. In general, the higher the fistula output, the greater the catabolic effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H322597\">",
"    <span class=\"h3\">",
"     Source control",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main goal in management of enteroatmospheric fistulas is to control the enteric contents at the source of the fistula. Exteriorization or proximal diversion of the fistula may be impossible because of massive edema and foreshortening of the mesentery.",
"   </p>",
"   <p>",
"    The &ldquo;floating stoma&rdquo; is one option to achieve source control in this situation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/40\">",
"     40",
"    </a>",
"    ]. To create a floating stoma, the hole in the gut is sutured to a similarly sized hole in a plastic sheet used as a temporary abdominal closure. A colostomy bag is then applied over the &ldquo;floating stoma&rdquo; controlling the fistula drainage until the wound granulates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18524954\">",
"    <span class=\"h3\">",
"     Negative pressure wound therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Negative pressure wound therapy, also called vacuum-assisted wound closure, has been widely applied to the management of enteroatmospheric fistulas [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/41\">",
"     41",
"    </a>",
"    ]. This approach minimizes dressing changes and protects the surrounding skin.",
"   </p>",
"   <p>",
"    The negative pressure wound therapy is useful for a patient with an established fistula. For these patients, a preferred technique is to intubate the fistula and bring the tube out through the hole in the sponge of the vacuum-assisted dressing (",
"    <a class=\"graphic graphic_figure graphicRef50588 \" href=\"UTD.htm?23/21/23889\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/6\">",
"     6",
"    </a>",
"    ]. Most of the drainage is collected in the tubes.",
"   </p>",
"   <p>",
"    However, caution must be used in applying a vacuum assisted dressing to exposed bowel without a fistula because this can lead to formation of a new fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=see_link&amp;anchor=H18#H18\">",
"     \"Negative pressure wound therapy\", section on 'Open abdomen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H322837\">",
"    <span class=\"h3\">",
"     Skin grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, an enteroatmospheric fistula is treated as a stoma and autologous skin grafts are applied to the surrounding granulation tissue. After the grafts heal, a variety of creative stoma management solutions can be adapted to the specific requirements of each fistula.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18524982\">",
"    <span class=\"h2\">",
"     Surgical closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical closure of an enteroatmospheric fistula and abdominal wall reconstruction should",
"    <strong>",
"     not",
"    </strong>",
"    be considered until the skin graft is supple and can be pinched between the thumb and index, which signifies the existence of a plane between the graft and underlying bowel.",
"   </p>",
"   <p>",
"    In most cases, a two-team approach is employed. A general surgery team performs the visceral dissection and fistula resection followed by a reconstruction team to close the abdomen. A careful preoperative assessment of the available tissue for reconstruction is important.",
"   </p>",
"   <p>",
"    The component separation technique is an excellent reconstructive option if the rectus abdominis muscle is intact [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/44\">",
"     44",
"    </a>",
"    ]. Defects of up to 10 cm in the upper abdomen, 20 cm in the mid-abdomen, and 8 cm in the lower abdomen can be closed with this technique. A variety of other pedicled or free flaps with microvascular reconstruction are available for use depending on the nature of the defect, available soft tissue components, and patient comorbidities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/34/32294?source=see_link\">",
"     \"Principles of component separation technique for complex abdominal wall defects and hernias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Biologic material such as acellular human [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/45\">",
"     45",
"    </a>",
"    ] or porcine [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/46\">",
"     46",
"    </a>",
"    ] dermal matrix can be used to close defects, although there appears to be a high incidence of late hernia formation with the use of these materials [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. As an example, a study of 10 patients with large abdominal defects showed that 100 percent of patients had successful defect closure with acellular human dermal matrix, but all patients developed significant laxity or hernias by one year of follow up [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/33/11799?source=see_link\">",
"     \"Reconstructive materials used in surgery: Classification and host response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1481384\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;With modern management strategies, most modern series report a mortality of 10 to 20 percent (",
"    <a class=\"graphic graphic_table graphicRef54412 \" href=\"UTD.htm?6/36/6731\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6152/abstract/1,2,4,9,21\">",
"     1,2,4,9,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/50/4897?source=see_link\">",
"       \"Patient information: Enterocutaneous fistula (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H322535\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An enterocutaneous fistula is a communication between the bowel lumen and the skin. An enteroatmospheric or exposed fistula refers to drainage of intestinal contents from an open abdomen with no overlying soft tissue. (See",
"      <a class=\"local\" href=\"#H18524881\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial treatment of an enterocutaneous fistula focuses on correction of fluid and electrolyte imbalance, abscess drainage and treatment of infection, correction of malnutrition, and meticulous fistula control and skin care. Approximately one-third of enterocutaneous fistulas heal spontaneously with these measures. Patients who do not respond to conservative measures should be referred to a center capable of providing complex multidisciplinary care. (See",
"      <a class=\"local\" href=\"#H18524895\">",
"       'Management of enterocutaneous fistulas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of surgery for an enterocutaneous fistula is to reestablish the continuity of the intestinal tract to achieve a tension-free closure of the abdomen with well-vascularized soft tissue. Before consideration of definitive repair of fistulas that fail to close spontaneously, patients should be nutritionally replete, free of infection, and have supple soft tissues adjacent to the fistula. Resection of a chronic enterocutaneous fistula is a complex life-threatening operation that requires careful planning, meticulous dissection to mobilize the entire intestinal tract, and resection of the segment of bowel serving as the source of the fistula. (See",
"      <a class=\"local\" href=\"#H18524932\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enteroatmospheric fistulas will not heal spontaneously because of the absence of overlying soft tissue. The main goal in management of enteroatmospheric fistulas is to control the enteric contents at the source of the fistula. &nbsp;In most cases, a fistula is treated as a stoma and autologous skin grafts are applied to the surrounding granulation tissue. Surgical closure of an enteroatmospheric fistula and abdominal wall reconstruction should",
"      <strong>",
"       not",
"      </strong>",
"      be considered until the skin graft is supple and can be pinched between the thumb and index, which signifies the existence of a plane between the graft and underlying bowel. (See",
"      <a class=\"local\" href=\"#H18524939\">",
"       'Management of enteroatmospheric fistulas'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/1\">",
"      Osborn C, Fischer JE. How I do it: gastrointestinal cutaneous fistulas. J Gastrointest Surg 2009; 13:2068.",
"     </a>",
"    </li>",
"    <li>",
"     Fischer JE, Evenson AR. Gastrointestinal-Cutanous Fistulae. In: Mastery of Surgery, Fifth, Fischer JE, Bland KI (Eds), Lippincott, Philadelphia 2007. Vol 2, p.1401.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/3\">",
"      Berry SM, Fischer JE. Classification and pathophysiology of enterocutaneous fistulas. Surg Clin North Am 1996; 76:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/4\">",
"      Schecter WP, Hirshberg A, Chang DS, et al. Enteric fistulas: principles of management. J Am Coll Surg 2009; 209:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/5\">",
"      Hollington P, Mawdsley J, Lim W, et al. An 11-year experience of enterocutaneous fistula. Br J Surg 2004; 91:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/6\">",
"      Al-Khoury G, Kaufman D, Hirshberg A. Improved control of exposed fistula in the open abdomen. J Am Coll Surg 2008; 206:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/7\">",
"      Schein M. What's new in postoperative enterocutaneous fistulas? World J Surg 2008; 32:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/8\">",
"      Schein M, Decker GA. Gastrointestinal fistulas associated with large abdominal wall defects: experience with 43 patients. Br J Surg 1990; 77:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/9\">",
"      Irving M, White R, Tresadern J. Three years' experience with an intestinal failure unit. Ann R Coll Surg Engl 1985; 67:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/10\">",
"      Sansoni B, Irving M. Small bowel fistulas. World J Surg 1985; 9:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/11\">",
"      CHAPMAN R, FORAN R, DUNPHY JE. MANAGEMENT OF INTESTINAL FISTULAS. Am J Surg 1964; 108:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/12\">",
"      Levy E, Frileux P, Cugnenc PH, et al. [Exposed fistula of the small intestine, a complication of peritonitis or laparotomy. Apropos of 120 cases]. Ann Chir 1986; 40:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/13\">",
"      Halversen RC, Hogle HH, Richards RC. Gastric and small bowel fistulas. Am J Surg 1969; 118:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/14\">",
"      Campos AC, Andrade DF, Campos GM, et al. A multivariate model to determine prognostic factors in gastrointestinal fistulas. J Am Coll Surg 1999; 188:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/15\">",
"      Fazio VW, Coutsoftides T, Steiger E. Factors influencing the outcome of treatment of small bowel cutaneous fistula. World J Surg 1983; 7:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/16\">",
"      Fischer JE. The pathophysiology of enterocutaneous fistulas. World J Surg 1983; 7:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/17\">",
"      Aguirre A, Fischer JE, Welch CE. The role of surgery and hyperalimentation in therapy of gastrointestinal-cutaneous fistulae. Ann Surg 1974; 180:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/18\">",
"      McIntyre PB, Ritchie JK, Hawley PR, et al. Management of enterocutaneous fistulas: a review of 132 cases. Br J Surg 1984; 71:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/19\">",
"      Prickett D, Montgomery R, Cheadle WG. External fistulas arising from the digestive tract. South Med J 1991; 84:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/20\">",
"      Sitges-Serra A, Jaurrieta E, Sitges-Creus A. Management of postoperative enterocutaneous fistulas: the roles of parenteral nutrition and surgery. Br J Surg 1982; 69:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/21\">",
"      Draus JM Jr, Huss SA, Harty NJ, et al. Enterocutaneous fistula: are treatments improving? Surgery 2006; 140:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/22\">",
"      Reber HA, Roberts C, Way LW, Dunphy JE. Management of external gastrointestinal fistulas. Ann Surg 1978; 188:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/23\">",
"      Kwon SH, Oh JH, Kim HJ, et al. Interventional management of gastrointestinal fistulas. Korean J Radiol 2008; 9:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/24\">",
"      Fulcher AS, Turner MA. Percutaneous drainage of enteric-related abscesses. Gastroenterologist 1996; 4:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/25\">",
"      Dudrick SJ, Maharaj AR, McKelvey AA. Artificial nutritional support in patients with gastrointestinal fistulas. World J Surg 1999; 23:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/26\">",
"      Stanga Z, Brunner A, Leuenberger M, et al. Nutrition in clinical practice-the refeeding syndrome: illustrative cases and guidelines for prevention and treatment. Eur J Clin Nutr 2008; 62:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/27\">",
"      Lloyd DA, Gabe SM, Windsor AC. Nutrition and management of enterocutaneous fistula. Br J Surg 2006; 93:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/28\">",
"      Alexander ES, Weinberg S, Clark RA, Belkin RD. Fistulas and sinus tracts: radiographic evaluation, management, and outcome. Gastrointest Radiol 1982; 7:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/29\">",
"      Martinez JL, Luque-de-Leon E, Mier J, et al. Systematic management of postoperative enterocutaneous fistulas: factors related to outcomes. World J Surg 2008; 32:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/30\">",
"      Cro C, George KJ, Donnelly J, et al. Vacuum assisted closure system in the management of enterocutaneous fistulae. Postgrad Med J 2002; 78:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/31\">",
"      Banwell P, Withey S, Holten I. The use of negative pressure to promote healing. Br J Plast Surg 1998; 51:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/32\">",
"      Wainstein DE, Fernandez E, Gonzalez D, et al. Treatment of high-output enterocutaneous fistulas with a vacuum-compaction device. A ten-year experience. World J Surg 2008; 32:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/33\">",
"      Makhdoom ZA, Komar MJ, Still CD. Nutrition and enterocutaneous fistulas. J Clin Gastroenterol 2000; 31:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/34\">",
"      Nubiola P, Badia JM, Martinez-Rodenas F, et al. Treatment of 27 postoperative enterocutaneous fistulas with the long half-life somatostatin analogue SMS 201-995. Ann Surg 1989; 210:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/35\">",
"      Hill GL. Operative strategy in the treatment of enterocutaneous fistulas. World J Surg 1983; 7:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/36\">",
"      Schecter WP, Ivatury RR, Rotondo MF, Hirshberg A. Open abdomen after trauma and abdominal sepsis: a strategy for management. J Am Coll Surg 2006; 203:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/37\">",
"      Jamshidi R, Schecter WP. Biological dressings for the management of enteric fistulas in the open abdomen: a preliminary report. Arch Surg 2007; 142:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/38\">",
"      Sarfeh IJ, Jakowatz JG. Surgical treatment of enteric 'bud' fistulas in contaminated wounds. A riskless extraperitoneal method using split-thickness skin grafts. Arch Surg 1992; 127:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/39\">",
"      Girard S, Sideman M, Spain DA. A novel approach to the problem of intestinal fistulization arising in patients managed with open peritoneal cavities. Am J Surg 2002; 184:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/40\">",
"      Subramaniam MH, Liscum KR, Hirshberg A. The floating stoma: a new technique for controlling exposed fistulae in abdominal trauma. J Trauma 2002; 53:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/41\">",
"      Boulanger K, Lemaire V, Jacquemin D. Vacuum-assisted closure of enterocutaneous fistula. Acta Chir Belg 2007; 107:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/42\">",
"      Rao M, Burke D, Finan PJ, Sagar PM. The use of vacuum-assisted closure of abdominal wounds: a word of caution. Colorectal Dis 2007; 9:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/43\">",
"      Fischer JE. A cautionary note: the use of vacuum-assisted closure systems in the treatment of gastrointestinal cutaneous fistula may be associated with higher mortality from subsequent fistula development. Am J Surg 2008; 196:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/44\">",
"      Shestak KC, Edington HJ, Johnson RR. The separation of anatomic components technique for the reconstruction of massive midline abdominal wall defects: anatomy, surgical technique, applications, and limitations revisited. Plast Reconstr Surg 2000; 105:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/45\">",
"      Maurice SM, Skeete DA. Use of human acellular dermal matrix for abdominal wall reconstructions. Am J Surg 2009; 197:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/46\">",
"      Hsu PW, Salgado CJ, Kent K, et al. Evaluation of porcine dermal collagen (Permacol) used in abdominal wall reconstruction. J Plast Reconstr Aesthet Surg 2009; 62:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/47\">",
"      de Moya MA, Dunham M, Inaba K, et al. Long-term outcome of acellular dermal matrix when used for large traumatic open abdomen. J Trauma 2008; 65:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6152/abstract/48\">",
"      Jin J, Rosen MJ, Blatnik J, et al. Use of acellular dermal matrix for complicated ventral hernia repair: does technique affect outcomes? J Am Coll Surg 2007; 205:654.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15157 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-2.133.93.82-E575B2020D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_0_6152=[""].join("\n");
var outline_f6_0_6152=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H322535\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18524881\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1480967\">",
"      PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18116253\">",
"      CLASSIFICATION OF ENTERIC FISTULAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H322734\">",
"      Enterocutaneous fistulas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H322742\">",
"      Enteroatmospheric (exposed) fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18524895\">",
"      MANAGEMENT OF ENTEROCUTANEOUS FISTULAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H320290\">",
"      Fluid and electrolyte imbalance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H320484\">",
"      Abscess drainage and treatment of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H320386\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1480975\">",
"      Fistulogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18524911\">",
"      Fistula control and skin care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18524932\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1481392\">",
"      - Duodenal fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18524939\">",
"      MANAGEMENT OF ENTEROATMOSPHERIC FISTULAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18524947\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H322894\">",
"      Superficial enteroatmospheric fistulas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H322677\">",
"      Deep enteroatmospheric fistulas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H322712\">",
"      - Nutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H322597\">",
"      - Source control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18524954\">",
"      - Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H322837\">",
"      - Skin grafts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18524982\">",
"      Surgical closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481384\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H322535\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15157\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15157|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/21/23889\" title=\"figure 1\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15157|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/50/15140\" title=\"picture 1\">",
"      Enteroatmospheric fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/15/33016\" title=\"picture 2\">",
"      Negative pressure wound dressing in situ",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15157|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/44/25291\" title=\"table 1\">",
"      Causes of enterocutaneous fistulae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/19/23868\" title=\"table 2\">",
"      Phases of management for enterocutaneous fistulae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/48/30476\" title=\"table 3\">",
"      Predictors of spontaneous closure of enterocutaneous fistulas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/36/6731\" title=\"table 4\">",
"      Mortality of gastrointestinal-cutaneous fistulae",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42819?source=related_link\">",
"      Acute diverticulitis complicated by fistula formation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=related_link\">",
"      Approach to the adult with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28903?source=related_link\">",
"      Clinical features, diagnosis, and prevention of pancreatic fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2218?source=related_link\">",
"      Management of patients with a colostomy or ileostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=related_link\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43801?source=related_link\">",
"      Overview of abdominal hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/50/4897?source=related_link\">",
"      Patient information: Enterocutaneous fistula (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26246?source=related_link\">",
"      Perianal abscess: Clinical manifestations, diagnosis, treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/34/32294?source=related_link\">",
"      Principles of component separation technique for complex abdominal wall defects and hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/33/11799?source=related_link\">",
"      Reconstructive materials used in surgery: Classification and host response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32951?source=related_link\">",
"      Rectovaginal, anovaginal, and colovesical fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23878?source=related_link\">",
"      Treatment of pancreatic fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44792?source=related_link\">",
"      Urogenital tract fistulas in women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_0_6153="Physiology of parturition";
var content_f6_0_6153=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Physiology of parturition",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/0/6153/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/0/6153/contributors\">",
"     Errol R Norwitz, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/0/6153/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/0/6153/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/0/6153/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/0/6153/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/0/6153/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Labor is a physiological event involving a sequential, integrated set of changes within the myometrium, decidua, and uterine cervix that occur gradually over a period of days to weeks. Biochemical connective tissue changes in the uterine cervix appear to precede uterine contractions and cervical dilation, and all of these events usually occur before rupture of the fetal membranes.",
"   </p>",
"   <p>",
"    Labor is characterized by an increase in myometrial activity or, more precisely, a change in the myometrial contractility pattern from \"contractures\" (long-lasting, low frequency activity) to \"contractions\" (high intensity, high frequency activity) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/1\">",
"     1",
"    </a>",
"    ], resulting in effacement and dilatation of the uterine cervix.",
"   </p>",
"   <p>",
"    Labor is a clinical diagnosis, classically defined by the triad of regular painful uterine contractions, progressive cervical effacement and dilatation, and show (bloody discharge). Cervical dilatation in the absence of uterine contractions is seen most commonly in the second trimester and is suggestive of cervical insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=see_link\">",
"     \"Cervical insufficiency\"",
"    </a>",
"    .) Similarly, the presence of uterine contractions in the absence of cervical change does not meet criteria for the diagnosis of labor. Such contractions are often attributed to \"false labor\" or uterine irritability.",
"   </p>",
"   <p>",
"    Labor and delivery are not passive processes by which uterine contractions push a rigid object through a fixed aperture. The ability of the fetus to successfully negotiate the pelvis during labor and delivery depends upon a complex interaction of three variables: power (uterine contractions), passenger (fetus), and passage (both bony pelvis and pelvic soft tissues). Although conventional wisdom dictates that powerful contractions are more likely to be associated with a successful outcome, there are no data to support this conclusion. Furthermore, precipitous labor probably results from low resistance of the pelvic soft tissues (the cervix in the first stage of labor and the muscles of the pelvic floor in the second stage) rather than from high myometrial activity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LABOR AT TERM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean duration of human singleton pregnancy is 280 days (40 weeks) from the first day of the last menstrual period. A term pregnancy is defined as the period from 259 to 293 days after the first day of the last menstrual period (37 to 41 and",
"    <span class=\"nowrap\">",
"     6/7th",
"    </span>",
"    weeks).",
"   </p>",
"   <p>",
"    Term labor may be regarded physiologically as a release from the inhibitory effects of pregnancy on the myometrium, rather than as an active process mediated by uterine stimulants. As an example, strips of myometrium obtained from a quiescent uterus at term and placed in an isotonic water bath will contract vigorously and spontaneously without added stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Nevertheless, both inhibitory and stimulatory mechanisms likely play a role in uterine activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHYSIOLOGICAL PHASES OF MYOMETRIAL ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The regulation of uterine activity during pregnancy can be divided into four distinct physiologic phases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Phase 0: inhibitors active",
"    </span>",
"    &nbsp;&mdash;&nbsp;Throughout most of pregnancy the uterus is maintained in a state of functional quiescence through the action of various putative inhibitors including, but not limited to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Progesterone",
"     </li>",
"     <li>",
"      Prostacyclin (prostaglandin I-2)",
"     </li>",
"     <li>",
"      Relaxin",
"     </li>",
"     <li>",
"      Parathyroid hormone-related peptide",
"     </li>",
"     <li>",
"      Nitric oxide",
"     </li>",
"     <li>",
"      Calcitonin gene-related peptide",
"     </li>",
"     <li>",
"      Adrenomedullin",
"     </li>",
"     <li>",
"      Vasoactive intestinal peptide.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Phase 1: myometrial activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As term approaches the uterus becomes activated in response to uterotropins, such as estrogen. This phase is characterized by increased expression of a series of contraction-associated proteins (CAPs) (including myometrial receptors for prostaglandins and oxytocin), activation of specific ion channels, and an increase in connexin-43 (a key component of gap junctions). An increase in gap junction formation between adjacent myometrial cells leads to electrical synchrony within the myometrium and allows for effective coordination of contractions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Phase 2: stimulatory phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following activation, the \"primed\" uterus can be stimulated to contract by the action of uterotonic agonists, such as the stimulatory prostaglandins E2 and F2 alpha and oxytocin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Phase 3: involution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involution of the uterus after delivery occurs during phase 3 and is mediated primarily by oxytocin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Parturition cascade",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is likely that a \"parturition cascade\" exists at term which removes the mechanisms maintaining uterine quiescence and recruits factors promoting uterine activity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/2,7,8\">",
"     2,7,8",
"    </a>",
"    ]. Given its teleological importance, such a cascade would likely have multiple redundant loops to ensure a fail-safe system of securing pregnancy success (and thus preserving the species). In such a model, each element is connected to the next in a sequential fashion, and many of the elements demonstrate positive feed-forward characteristics typical of a cascade mechanism.",
"   </p>",
"   <p>",
"    The sequential recruitment of signals that serve to augment the labor process suggest that it may not be possible to single out any one signaling mechanism as being responsible for the initiation of labor. Therefore, it is prudent to describe such mechanisms as being responsible for \"promoting\", rather than \"initiating\", the process of labor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     THE ROLE OF THE FETUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considerable evidence suggests that in most viviparous animals the fetus controls the timing of onset of labor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. During the Hippocratic period, the fetus was thought to be positioned head down at term so it could kick its legs up against the fundus of the uterus, thereby propelling itself through the birth canal. While we have moved away from this simple and mechanical view of labor, the factors responsible for the initiation and maintenance of labor at term are not well defined. Initial investigations focused on endocrine events, such as changes in the profile of circulating hormone levels in the maternal and fetal circulations. Subsequent studies have concentrated on the dynamic biochemical dialogue between the fetus and mother",
"    <span class=\"nowrap\">",
"     (paracrine/autocrine",
"    </span>",
"    events) in an attempt to understand the molecular mechanisms that regulate such interactions. The genetic regulation of the molecular events that occur during parturition are also being investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hypothesis that the fetus is in control of the timing of labor was elegantly demonstrated in domestic ruminants [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. As an example, parturition in sheep is initiated by a sharp rise in fetal adrenal cortisol secretion related to increased fetal concentrations of and responsiveness to corticotropin&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/16\">",
"     16",
"    </a>",
"    ]. Cortisol acts on placental enzymes active in the biosynthesis of estrogens from progesterone to augment secretion of estrogen and decrease progesterone production. The resulting increase in the ratio of estrogen to progesterone stimulates placental release of prostaglandin F2 alpha, which enhances the myometrial response to oxytocin and stimulates contractions.",
"   </p>",
"   <p>",
"    However, the human placenta lacks the glucocorticoid-inducible",
"    <span class=\"nowrap\">",
"     17-alpha-hydroxylase/17,20-lyase",
"    </span>",
"    enzyme that is essential to this process [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/12,19,20\">",
"     12,19,20",
"    </a>",
"    ]. Therefore, activation of the hypothalamic-pituitary-adrenal axis in humans likely results in a different mechanism for initiation of labor (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Estrogen'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    A role for the fetal genotype in the initiation of labor was suggested by horse-donkey crossbreeding experiments that resulted in a gestational length intermediate between that of horses (340 days) and that of donkeys (365 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/12,19\">",
"     12,19",
"    </a>",
"    ]. This concept holds true whether pregnancy is maintained by the fetoplacental unit (as in the sheep and human) or by extrauterine tissues (as in the mouse and goat) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The slow progress in our understanding of the biochemical mechanisms involved in the process of labor in humans reflects, in large part, the difficulty in extrapolating from the endocrine-control mechanisms in various animals to the",
"    <span class=\"nowrap\">",
"     paracrine/autocrine",
"    </span>",
"    mechanisms of human parturition, processes that preclude direct investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MYOMETRIAL ACTIVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of whether the trigger originates within or outside the fetus, the final common pathway for labor ends in the maternal tissues of the uterus and is characterized by the development of regular phasic uterine contractions. As in other smooth muscles, myometrial contractions are mediated through ATP-dependent binding of myosin to actin. This interaction is dependent upon the phosphorylation of myosin light chain by a",
"    <span class=\"nowrap\">",
"     calcium/calmodulin-dependent",
"    </span>",
"    enzyme, myosin light chain kinase. The availability of free intracellular calcium is thus a key modulator of myometrial contractility.",
"   </p>",
"   <p>",
"    GTP-binding proteins (G-proteins) play a pivotal role in myometrial contractility by coupling cell membrane receptors to effector enzymes and ion channels. As an example, activation of beta-adrenergic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PGE2 receptors promote myometrial relaxation via the",
"    <span class=\"nowrap\">",
"     Gas/adenyl",
"    </span>",
"    <span class=\"nowrap\">",
"     cyclase/cAMP",
"    </span>",
"    signal transduction pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/3,21\">",
"     3,21",
"    </a>",
"    ]. Oxytocin receptors, on the other hand, couple to",
"    <span class=\"nowrap\">",
"     Gaq/Gai/phospholipase",
"    </span>",
"    C pathways leading to an increase in inositol-1,4,5-trisphosphate (which releases calcium from the sarcoplasmic reticulum) and 1,2-diacylglycerol (which activates protein kinase C) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/22\">",
"     22",
"    </a>",
"    ]. The end result is an increase in intracellular calcium and myometrial contractions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pregnancy affects not only cell surface receptor concentrations, but also the concentrations and coupling of the various G-proteins. Gaq and Gai are expressed at similar levels in nonpregnant and pregnant myometrium, both before and after the onset of labor. By comparison, Gas levels are higher in pregnant as compared with nonpregnant myometrium [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/24\">",
"     24",
"    </a>",
"    ], and levels have been shown to decrease before labor, both at term and preterm [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/25\">",
"     25",
"    </a>",
"    ]. It has been suggested, therefore, that labor results from a down-regulation of pathways that favor uterine quiescence leading to a relative dominance of stimulatory pathways that increase intracellular calcium bioavailability and promote myometrial contractility [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other myometrial factors (eg, mechanotransduction via stretching or shortening) which could affect initiation, frequency, or strength of contractions are under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to vascular smooth muscle, myometrial cells have sparse innervation, which is further reduced during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/28\">",
"     28",
"    </a>",
"    ]. The regulation of the contractile mechanism of the uterus is therefore largely humoral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dependent upon intrinsic factors within myometrial cells. A number of hormones have been implicated in this regard. Some of these are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     HORMONES INVOLVED IN THE PARTURITIONAL CASCADE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comprehensive analyses of each of the individual",
"    <span class=\"nowrap\">",
"     paracrine/autocrine",
"    </span>",
"    pathways involved in the process of labor have been reviewed in detailed elsewhere&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/2,5-9,15,19\">",
"     2,5-9,15,19",
"    </a>",
"    ]. A few of the hormones implicated in this process are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prostaglandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostaglandins are predominantly",
"    <span class=\"nowrap\">",
"     paracrine/autocrine",
"    </span>",
"    hormones (ie, they act locally at their site of production on contiguous cells). An increase in uterine prostaglandin biosynthesis is a consistent element in the transition into labor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/29\">",
"     29",
"    </a>",
"    ], and is probably common to all species [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/30\">",
"     30",
"    </a>",
"    ]. It seems likely that hormonal factors controlling the final pathway for the onset of labor in women, both at term and preterm, is an increased synthesis of prostaglandins of the E and F series within the uterine compartment, predominantly from the decidua and fetal membranes. The evidence can be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human uterine tissues are selectively enriched with arachidonic acid, the obligate precursor of prostaglandin biosynthesis.",
"     </li>",
"     <li>",
"      Concentrations of prostaglandins in amniotic fluid and in maternal plasma and urine are increased during parturition [",
"      <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/29,31,32\">",
"       29,31,32",
"      </a>",
"      ]. Moreover, prostaglandin levels appear to rise prior to the onset of myometrial concentrations suggesting that they are a cause, rather than a consequence, of labor [",
"      <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The intraamniotic, intravenous, or vaginal administration of exogenous prostaglandins can initiate labor at any stage of gestation and in all species [",
"      <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prostaglandins have been implicated in the three events most temporally related to the onset of labor [",
"      <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/4,35\">",
"       4,35",
"      </a>",
"      ]: the onset of synchronous uterine contractions, cervical ripening, and the increase in myometrial sensitivity to oxytocin due to an increase in myometrial gap junction formation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      oxytocin receptor concentrations.",
"     </li>",
"     <li>",
"      Inhibitors of prostaglandin synthesis (including cyclooxygenase inhibitors such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      ) are capable of suppressing myometrial contractility both in vitro and in vivo, and of prolonging the length of gestation [",
"      <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/4,36,37\">",
"       4,36,37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these data affirm the critical role of prostaglandins, especially PGF2 alpha, in the initiation of labor. It appears that withdrawal of fetal-paracrine support of the quiescent uterus leads to decidual activation, followed by PGF2 alpha release and subsequent spontaneous labor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/32\">",
"     32",
"    </a>",
"    ]. PGE2 appears to play a more important role in cervical ripening (a remodeling process in which collagen is degraded leading to softening of the cervix) and rupture of the fetal membranes than in uterine contractility [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Progesterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of a progesterone receptor antagonist [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/38,39\">",
"     38,39",
"    </a>",
"    ] or removal of the corpus luteum [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/40\">",
"     40",
"    </a>",
"    ] readily induces abortion in early pregnancy (before 7 weeks of gestation), suggesting that progesterone is necessary for early pregnancy maintenance. Administration of exogenous progesterone after early lutectomy prevents abortion, further supporting the hypothesis that ovarian progesterone production is essential in maintenance of early pregnancy. Placental progesterone production becomes important between 7 and 9 weeks, and the placenta is the dominant source of progesterone thereafter.",
"   </p>",
"   <p>",
"    However, the role of progesterone in late pregnancy is not as well defined [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/41\">",
"     41",
"    </a>",
"    ]. Progesterone withdrawal does not occur in all women before labor, and mean circulating progesterone levels during labor are similar to those measured one week prior [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/42\">",
"     42",
"    </a>",
"    ]. Moreover, the administration of progesterone late in pregnancy does not delay the onset of labor in primates [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/43\">",
"     43",
"    </a>",
"    ], and progesterone receptor antagonists are not capable of inducing labor at term (although they may promote cervical ripening) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Finally, pregnancies complicated by maternal hypobetalipoproteinemia (LDL deficiency with very low levels of progesterone) culminate in spontaneous labor at term without incident [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data suggest that progesterone withdrawal is not a prerequisite for labor in humans. This is in contrast to most mammalian species in which progesterone withdrawal is an essential component of parturition [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/47\">",
"     47",
"    </a>",
"    ]. However, circulating hormone concentrations do not necessarily reflect activity at the tissue level. The onset of labor in women may be preceded by a physiologic withdrawal of progesterone activity (\"functional progesterone withdrawal\") at the level of the uterus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, there is increasing evidence that supplemental progesterone administration &nbsp;reduces the rate of preterm birth in high risk women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11994?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention of spontaneous preterm birth\", section on 'Supplemental progesterone'",
"    </a>",
"    .) Further investigation is needed to confirm the effectiveness of progesterone supplementation and to understand its mechanism of action. It has not been studied as a tocolytic for active preterm labor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The placenta is the primary source of estrogen biosynthesis during pregnancy. Estrogens do not themselves cause myometrial contractions, and maternal administration of estradiol to rhesus macaques from 130 days of gestation has no effect on length of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/48\">",
"     48",
"    </a>",
"    ]. Instead, estrogens act by upregulating myometrial gap junctions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/49\">",
"     49",
"    </a>",
"    ] and uterotonic receptors (including L-type calcium channels and oxytocin receptors) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/50\">",
"     50",
"    </a>",
"    ], thereby enhancing the capacity of the myometrium to generate contractions.",
"   </p>",
"   <p>",
"    Longitudinal measurements of circulating estrogen concentrations prior to the onset of labor show an increase in all primate species [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/51\">",
"     51",
"    </a>",
"    ]. Because the primate placenta is an incomplete steroidogenic organ, placental estrogen synthesis has an obligate need for C-19 steroid precursors (it cannot synthesize estrogen from progesterone) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. The fetal adrenal provides an abundant C19 estrogen precursor (dehydroepiandrostenedione) directly from its intermediate (fetal) zone. In the rhesus monkey, continuous infusion of C19 precursor (androstenedione) leads to preterm delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. This effect is blocked by concurrent infusion of an aromatase inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/54\">",
"     54",
"    </a>",
"    ], demonstrating that conversion to estrogen is important in promoting contractions. A similar effect has been shown using a continuous intraamniotic infusion of estrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/48\">",
"     48",
"    </a>",
"    ]. However, systemic infusion of estrogen failed to induce delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/48\">",
"     48",
"    </a>",
"    ], suggesting that the action of estrogen is likely",
"    <span class=\"nowrap\">",
"     paracrine/autocrine.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Oxytocin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxytocin is a peptide hormone synthesized in the hypothalamus and released from the posterior pituitary in a pulsatile fashion. Its biologic half-life is approximately three to four minutes, but appears shorter when higher doses are infused. Oxytocin is inactivated in the liver and kidney, although during pregnancy it is primarily degraded by placental oxytocinase. The evidence in support of a role for oxytocin in parturition can be summarized briefly as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oxytocin is the most potent endogenous uterotonic agent, and is capable of stimulating uterine contractions at intravenous infusion rates of 1 to 2",
"      <span class=\"nowrap\">",
"       mU/min",
"      </span>",
"      at term [",
"      <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/55,56\">",
"       55,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The frequency and amplitude of oxytocin-induced uterine contractions are identical to those occurring during spontaneous labor.",
"     </li>",
"     <li>",
"      More than 100",
"      <span class=\"nowrap\">",
"       mU/min",
"      </span>",
"      oxytocin is needed to elicit uterine contractions in nonpregnant women, while 16",
"      <span class=\"nowrap\">",
"       mU/",
"      </span>",
"      min is sufficient to elicit contractions at 20 weeks of gestation, 2 to 3",
"      <span class=\"nowrap\">",
"       mU/min",
"      </span>",
"      at 32 weeks, and 1",
"      <span class=\"nowrap\">",
"       mU/min",
"      </span>",
"      at term [",
"      <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Uterine contractions can be induced by electrical stimulation of the posterior pituitary gland or by nipple stimulation, presumably by increasing oxytocin concentrations in the blood.",
"     </li>",
"     <li>",
"      Oxytocin analogues that act as competitive antagonists of endogenous oxytocin effectively inhibit labor [",
"      <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Circulating levels of oxytocin do not change significantly during pregnancy or prior to the onset of labor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. However, myometrial oxytocin receptor concentrations increase approximately 100 to 200-fold during pregnancy, reaching a maximum during early labor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/55,56,58,59\">",
"     55,56,58,59",
"    </a>",
"    ]. This rise in receptor concentration accounts for the increased sensitivity of the myometrium to circulating levels of oxytocin during the second half of pregnancy.",
"   </p>",
"   <p>",
"    Specific high-affinity oxytocin receptors have also been isolated apart from the myometrium in the human amnion and decidua parietalis, but not decidua vera [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/50,55\">",
"     50,55",
"    </a>",
"    ]. Neither amnion nor decidual cells are contractile, and the action of oxytocin on these tissues is uncertain. Oxytocin may play a dual role in the mechanism of parturition [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/55,58\">",
"     55,58",
"    </a>",
"    ]: it may act directly through oxytocin receptor-mediated and nonreceptor, voltage-mediated calcium channels to affect intracellular biochemical pathways and promote uterine contractions or it may act indirectly through stimulation of amniotic and decidual prostaglandin production. Induction of labor at term is successful only when the oxytocin infusion is associated with an increase in PGF2 alpha production, in spite of apparently adequate uterine contractions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies examining fetal pituitary oxytocin production, the umbilical arteriovenous difference in plasma oxytocin concentration, amniotic fluid oxytocin levels, and fetal urinary oxytocin output demonstrate conclusively that the fetus secretes oxytocin into the maternal circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/55,60\">",
"     55,60",
"    </a>",
"    ]. Furthermore, the calculated oxytocin secretion rates from the fetus suggest an increase from a baseline of 1",
"    <span class=\"nowrap\">",
"     mU/min",
"    </span>",
"    prior to labor to approximately 3",
"    <span class=\"nowrap\">",
"     mU/min",
"    </span>",
"    after spontaneous labor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/60\">",
"     60",
"    </a>",
"    ]. The latter is similar to the dose of oxytocin normally administered to women to induce labor at term (2 to 8",
"    <span class=\"nowrap\">",
"     mU/min).",
"    </span>",
"    Although maternal serum oxytocin levels are not increased prior to the onset of labor or during the first stage of labor, oxytocin derived from the fetus and possibly from local decidual and other uterine sources could act on myometrial oxytocin receptors in a",
"    <span class=\"nowrap\">",
"     paracrine/",
"    </span>",
"    autocrine fashion to initiate and maintain effective uterine contractions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=see_link\">",
"     \"Principles of labor induction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unlikely that oxytocin provides the trigger for the initiation of labor, but the release of oxytocin during labor results in more forceful uterine contractions and undoubtedly facilitates delivery of the fetus and placenta. The existence of the so-called Ferguson reflex (release of maternal oxytocin from the posterior pituitary in response to distention of the cervix",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vagina) remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hypothalamic-pituitary-adrenal factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The final common pathway for initiation of labor appears to be activation of the fetal hypothalamic-pituitary-adrenal axis, which is probably a common pathway for all species.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Corticotropin releasing hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activation of the fetal hypothalamic-pituitary-adrenal axis during the latter part of pregnancy results in release of large amounts of fetal cortisol [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Glucocorticoids (including cortisol) are potent stimulants of placental corticotropin releasing hormone (CRH) production, in contrast to their negative effect on hypothalamic CRH production &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/64\">",
"     64",
"    </a>",
"    ]. Inflammatory cytokines, catecholamines, acetylcholine, and oxytocin also increase placental CRH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/6\">",
"     6",
"    </a>",
"    ], while progesterone and nitric oxide (NO) decrease placental CRH release. Circulating maternal plasma CRH levels increase progressively throughout the latter half of pregnancy, with a dramatic increase in the final six to eight weeks before delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During pregnancy, CRH bioactivity (as measured by its ability to promote ACTH release from the pituitary and to stimulate decidual PGE2 production) is decreased due to an increase in high-affinity CRH-binding protein (CRH-BP). However, in the last three to five weeks of gestation, CRH-BP concentrations fall, resulting in a rapid rise in circulating free CRH [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with an early rapid rise in plasma CRH tend to deliver earlier and those with a slow rise tend to deliver later, suggesting that production of CRH is an important factor in the timing of delivery. This hypothesis has been termed the \"placental clock\" [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CRH has no direct inotropic action on human myometrium, but the increase in placental CRH at term is thought to have multiple actions on the uterus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/68\">",
"     68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is secreted back into the fetal compartment where it can act to drive pituitary ACTH release, thereby providing a positive feed-forward loop for labor",
"     </li>",
"     <li>",
"      It may act locally within the placenta to promote fetoplacental vasodilatation [",
"      <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/69\">",
"       69",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      It can directly and preferentially stimulate DHEA-S secretion in fetal adrenal cortical cells via a protein kinase system [",
"      <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/70,71\">",
"       70,71",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      It exerts effects on the uterus and cervix by upregulation of the nitric oxide pathway and by augmenting estrogen effects on these tissues [",
"      <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/72\">",
"       72",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      It enhances prostaglandin production in the amnion, chorion and decidua",
"     </li>",
"     <li>",
"      It primes the myometrium and potentiates the effects of oxytocin [",
"      <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/73\">",
"       73",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;These hormones have several actions that can also help prepare the uterus for labor.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoids act directly to upregulate prostaglandin production in fetal membranes at term [",
"      <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/6,74\">",
"       6,74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cortisol appears to stimulate expression of placental (but not hypothalamic) CRH in vitro [",
"      <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/64\">",
"       64",
"      </a>",
"      ]. Studies demonstrating an increase in circulating CRH concentrations (as well as a decrease in ACTH and cortisol levels) in women receiving antepartum glucocorticoids to promote fetal lung maturation suggest that this mechanism may also be operative in vivo [",
"      <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/75,76\">",
"       75,76",
"      </a>",
"      ]. In addition, measurement of elevated maternal plasma CRH levels between 28 and 30 weeks of gestation may predict women at increased risk of preterm delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In addition, cortisol enhances amnionic cyclooxygenase to enhance prostaglandin synthesis and inhibits chorionic prostaglandin dehydrogenase activity, thereby preventing prostaglandin metabolism [",
"      <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/6,68\">",
"       6,68",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these data suggest the gradual increase in fetal pituitary-adrenal activity over the last few weeks of gestation may have a role in the initiation of labor at term. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=see_link\">",
"     \"Pathogenesis of spontaneous preterm birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various neuropeptides and hormones can affect myometrial contractility. The concentration of some of these agents changes in maternal serum during pregnancy suggesting that they might act in an endocrine fashion, while others are produced locally within myometrial smooth muscle cells and act in an",
"    <span class=\"nowrap\">",
"     autocrine/paracrine",
"    </span>",
"    manner. However, their role in the initiation and maintenance of labor at term remains controversial. Some of these factors are illustrated below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Parathyroid hormone-related peptide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parathyroid hormone-related peptide is a potent smooth muscle relaxant capable of inhibiting oxytocin-induced contractions in baboons [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/78\">",
"     78",
"    </a>",
"    ]. It is unclear whether it has a physiologically important role in maintaining uterine quiescence prior to the onset of labor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Luteinizing hormone/human chorionic gonadotropin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Luteinizing",
"    <span class=\"nowrap\">",
"     hormone/human",
"    </span>",
"    chorionic gonadotropin may be important for maintaining uterine quiescence, especially in the first half of pregnancy. Human chorionic gonadotropin decreases gap junction formation in strips of myometrium in vitro, leading to a decrease in contraction frequency and intensity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/79\">",
"     79",
"    </a>",
"    ]. This effect is likely mediated through the adenyl cyclase signal transduction system resulting in an increase in intracellular cAMP, which favors uterine relaxation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Relaxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relaxin is a member of the insulin-like growth factor family of proteins. Plasma levels are highest at 8 to 12 weeks of gestation and thereafter decline to low levels, which persist until term [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/80\">",
"     80",
"    </a>",
"    ]. The primary source of relaxin is thought to be the corpus luteum.",
"   </p>",
"   <p>",
"    Relaxin appears to act indirectly to promote myometrial relaxation by stimulating myometrial prostacyclin production. This effect can be negated by inhibitors of prostaglandin synthesis. Relaxin also has been implicated in cervical ripening",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rupture of the fetal membranes, but this remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytokines have long been implicated in the pathophysiology of preterm labor associated with intraamniotic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/82\">",
"     82",
"    </a>",
"    ]. These agents may also be a component of the process of normal term labor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. Proinflammatory mediator levels (IL-1, IL-6, TNF-alpha) appear to increase in the maternal peripheral circulation before the onset of spontaneous term labor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/86\">",
"     86",
"    </a>",
"    ]. The developing fetus may produce physical and hormonal signals that stimulate macrophage migration to the uterus, with release of cytokines and activation of inflammatory transcription factors.",
"   </p>",
"   <p>",
"    Concentrations of interleukin (IL) -8 (but not IL-2 or tumor necrosis factor alpha) in human myometrium, decidua, and fetal membranes are increased during labor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/83\">",
"     83",
"    </a>",
"    ]. IL-8 is a potent chemotactic cytokine acting primarily on neutrophils. It may cause an increase in collagenase enzyme activity leading to cervical ripening",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spontaneous rupture of membranes. Moreover, cytokines and eicosanoids appear to interact and to accelerate each other's production in a cascade-like fashion, resulting in further increases in prostaglandin production [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/87\">",
"     87",
"    </a>",
"    ]. It has also been proposed that the increased inflammatory response promotes uterine contractility via direct activation of contractile genes (eg, COX-2, oxytocin receptor, connexin)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impairment of the capacity of progesterone to mediate uterine quiescence [",
"    <a class=\"abstract\" href=\"UTD.htm?6/0/6153/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human labor at term is a multifactorial physiological event involving an integrated set of changes within the maternal tissues of the uterus (myometrium, decidua, and uterine cervix) which occur gradually over a period of days to weeks.",
"     </li>",
"     <li>",
"      Such changes include, but are not limited to, an increase in prostaglandin synthesis and release within the uterus, an increase in myometrial gap junction formation, and up-regulation of myometrial oxytocin receptors (uterine activation).",
"     </li>",
"     <li>",
"      Once the myometrium and cervix are prepared, endocrine",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <span class=\"nowrap\">",
"       paracrine/autocrine",
"      </span>",
"      factors from the fetoplacental unit bring about a switch in the pattern of myometrial activity from irregular contractures to regular contractions (uterine stimulation).",
"     </li>",
"     <li>",
"      The fetus appears to control the initiation of labor by coordinating the switch in myometrial activity via placental steroid hormone production, mechanical distension of the uterus, and by secretion of neurohypophyseal hormones and other stimulators of prostaglandin synthesis.",
"     </li>",
"     <li>",
"      Labor is a clinical diagnosis based upon regular painful uterine contractions, progressive cervical effacement and dilatation, and a show (bloody discharge).",
"     </li>",
"     <li>",
"      The ability of the fetus to successfully negotiate the pelvis during labor and delivery is dependent on the complex interaction of three variables: the powers, the passenger, and the passage.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/1\">",
"      Nathanielsz PW, Giussani DA, Wu WX. Stimulation of the switch in myometrial activity from contractures to contractions in the pregnant sheep and nonhuman primate. Equine Vet J Suppl 1997; :83.",
"     </a>",
"    </li>",
"    <li>",
"     Norwitz, ER, Robinson JN, Repke, JT. Labor and Delivery. In: Obstetrics: Normal and Problem Pregnancies, 4th ed, Gabbe SG, Niebyl JR, Simpson JL (Eds), W.B. Saunders Company, New York 2001. p. 353.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/3\">",
"      L&oacute;pez Bernal A, Rivera J, Europe-Finner GN, et al. Parturition: activation of stimulatory pathways or loss of uterine quiescence? Adv Exp Med Biol 1995; 395:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/4\">",
"      Garrioch DB. The effect of indomethacin on spontaneous activity in the isolated human myometrium and on the response to oxytocin and prostaglandin. Br J Obstet Gynaecol 1978; 85:47.",
"     </a>",
"    </li>",
"    <li>",
"     MacDonald, PC. Parturition: Biomolecular and physiologic process. In: Williams Obstetrics, Cunningham FG, MacDonald, PC, Gant, NF, Leveno, KJ, Gilstrap, LC III (Eds), 19th ed, Appleton &amp; Lange, Connecticut 1993. p. 298.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/6\">",
"      Challis, JRG, Gibb, W. Control of parturition. Prenat Neonat Med 1996; 1:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/7\">",
"      Norwitz ER, Robinson JN, Challis JR. The control of labor. N Engl J Med 1999; 341:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/8\">",
"      Smith R. Parturition. N Engl J Med 2007; 356:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/9\">",
"      Myers DA, Nathanielsz PW. Biologic basis of term and preterm labor. Clin Perinatol 1993; 20:9.",
"     </a>",
"    </li>",
"    <li>",
"     Thorburn, GD, Challis, JRG, Robinson, JS. The endocrinology of parturition. In: Cellular Biology of the Uterus, Wynn, RM (Ed), Plenum Press, New York 1977. p. 653.",
"    </li>",
"    <li>",
"     Casey, LM, MacDonald, PC. The initiation of labour in women: Regulation of phospholipid and arachidonic acid metabolism and of prostaglandin production. In: Seminars in Perinatology, vol. 10, Creasy, RK, Warshaw, JB (Eds), Irvine &amp; Stratton, Florida 1986. p. 270.",
"    </li>",
"    <li>",
"     Liggins, GC. The onset of labour: An overview. In: The onset of labour: Cellular and integrative mechanisms. A National Institute of Child Health and Human Development Research Planning Workshop (November 29-December 1, 1987), McNellis, D, Challis, JRG, MacDonald, PC, Nathanielsz, PW, Roberts, JM (Eds), Perinatology Press, Ithaca, New York 1988. p. 1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/13\">",
"      Huber A, Hudelist G, Czerwenka K, et al. Gene expression profiling of cervical tissue during physiological cervical effacement. Obstet Gynecol 2005; 105:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/14\">",
"      Duff P, Huff RW, Gibbs RS. Management of premature rupture of membranes and unfavorable cervix in term pregnancy. Obstet Gynecol 1984; 63:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/15\">",
"      Norwitz, ER, Robinson, JN, Repke, JT. The initiation of parturition: A comparative analysis across the species. Current Problems Obstet Gynecol Fertil 1999; 22:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/16\">",
"      Liggins GC, Fairclough RJ, Grieves SA, et al. The mechanism of initiation of parturition in the ewe. Recent Prog Horm Res 1973; 29:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/17\">",
"      Flint, APF, Anderson, ABM, Steele, PA, et al. The mechanism by which fetal cortisol controls the onset of parturition in the sheep. Biochem Soc Trans 1975; 3:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/18\">",
"      Matthews SG, Challis JR. Regulation of the hypothalamo-pituitary-adrenocortical axis in fetal sheep. Trends Endocrinol Metab 1996; 7:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/19\">",
"      Liggins GC. Initiation of labour. Biol Neonate 1989; 55:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/20\">",
"      Cinque B, Navarretta V, Benedetto MT, et al. Labor in humans: 1. Progesterone, 20 alpha-dihydro-progesterone, estrone and 17 beta-estradiol in near placental and most distant human amnion and chorion laeve in various stages of labor at term. J Endocrinol Invest 1986; 9:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/21\">",
"      Garfield RE, Blennerhassett MG, Miller SM. Control of myometrial contractility: role and regulation of gap junctions. Oxf Rev Reprod Biol 1988; 10:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/22\">",
"      Phaneuf S, Europe-Finner GN, Varney M, et al. Oxytocin-stimulated phosphoinositide hydrolysis in human myometrial cells: involvement of pertussis toxin-sensitive and -insensitive G-proteins. J Endocrinol 1993; 136:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/23\">",
"      Phaneuf S, Europe-Finner GN, Carrasco MP, et al. Oxytocin signalling in human myometrium. Adv Exp Med Biol 1995; 395:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/24\">",
"      Europe-Finner GN, Phaneuf S, Watson SP, L&oacute;pez Bernal A. Identification and expression of G-proteins in human myometrium: up-regulation of G alpha s in pregnancy. Endocrinology 1993; 132:2484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/25\">",
"      Europe-Finner GN, Phaneuf S, Tolkovsky AM, et al. Down-regulation of G alpha s in human myometrium in term and preterm labor: a mechanism for parturition. J Clin Endocrinol Metab 1994; 79:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/26\">",
"      Hurd WW, Gibbs SG, Ventolini G, et al. Shortening increases spontaneous contractility in myometrium from pregnant women at term. Am J Obstet Gynecol 2005; 192:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/27\">",
"      Terzidou V, Sooranna SR, Kim LU, et al. Mechanical stretch up-regulates the human oxytocin receptor in primary human uterine myocytes. J Clin Endocrinol Metab 2005; 90:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/28\">",
"      Pauerstein CJ, Zauder HL. Autonomic innervation, sex steroids and uterine contractility. Obstet Gynecol Surv 1970; 25:Suppl:617.",
"     </a>",
"    </li>",
"    <li>",
"     Keirse, MJNC. Endogenous prostaglandins in human parturition. In: Human Parturition. Keirse, MJNC, Anderson, ABM, Bennebroek-Gravenhorstm, J, (Eds), Leiden University Press, Leiden 1979. p. 101.",
"    </li>",
"    <li>",
"     Liggins, GC. Initiation of parturition. In: Fetal Endocrinology, Novy, MJ, Resko, JA, (Eds), Academic Press, New York 1981. p. 211.",
"    </li>",
"    <li>",
"     Keirse, MJNC, Turnbull, AC. Prostaglandins in amniotic fluid during late pregnancy and labour. J Obstet Gynaecol Br Commonw 1973: 80:970.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/32\">",
"      Casey ML, MacDonald PC. Biomolecular processes in the initiation of parturition: decidual activation. Clin Obstet Gynecol 1988; 31:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/33\">",
"      Romero R, Munoz H, Gomez R, et al. Increase in prostaglandin bioavailability precedes the onset of human parturition. Prostaglandins Leukot Essent Fatty Acids 1996; 54:187.",
"     </a>",
"    </li>",
"    <li>",
"     Casey, LM, MacDonald, PC. The initiation of labour in women: Regulation of phospholipid and arachidonic acid metabolism and of prostaglandin production. In: Seminars in Perinatology, Creasy, RK, Warshaw, JB, (Eds), Irvine &amp; Stratton, Florida 1986. p. 270.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/35\">",
"      Karim SM, Hillier K. Prostaglandins in the control of animal and human reproduction. Br Med Bull 1979; 35:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/36\">",
"      Zuckerman H, Reiss U, Rubinstein I. Inhibition of human premature labor by indomethacin. Obstet Gynecol 1974; 44:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/37\">",
"      Wigvist N, Lundstr&ouml;m V, Gr&eacute;en K. Premature labor and indomethacin. Prostaglandins 1975; 10:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/38\">",
"      Peyron R, Aub&eacute;ny E, Targosz V, et al. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med 1993; 328:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/39\">",
"      Spitz IM, Bardin CW. Mifepristone (RU 486)--a modulator of progestin and glucocorticoid action. N Engl J Med 1993; 329:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/40\">",
"      Csapo AI, Pulkkinen MO, Wiest WG. Effects of luteectomy and progesterone replacement therapy in early pregnant patients. Am J Obstet Gynecol 1973; 115:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/41\">",
"      Zakar T, Mesiano S. How does progesterone relax the uterus in pregnancy? N Engl J Med 2011; 364:972.",
"     </a>",
"    </li>",
"    <li>",
"     Turnbull, AC. The endocrine control of labour. In: Obstetrics, Turnbull, AC, Chamberlain, G, (Eds), Churchill Livingston, London 1989. p. 189.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/43\">",
"      Haluska GJ, Cook MJ, Novy MJ. Inhibition and augmentation of progesterone production during pregnancy: effects on parturition in rhesus monkeys. Am J Obstet Gynecol 1997; 176:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/44\">",
"      Frydman R, Lelaidier C, Baton-Saint-Mleux C, et al. Labor induction in women at term with mifepristone (RU 486): a double-blind, randomized, placebo-controlled study. Obstet Gynecol 1992; 80:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/45\">",
"      Elliott CL, Brennand JE, Calder AA. The effects of mifepristone on cervical ripening and labor induction in primigravidae. Obstet Gynecol 1998; 92:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/46\">",
"      Parker CR Jr, Illingworth DR, Bissonnette J, Carr BR. Endocrine changes during pregnancy in a patient with homozygous familial hypobetalipoproteinemia. N Engl J Med 1986; 314:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/47\">",
"      Zakar T, Hertelendy F. Progesterone withdrawal: key to parturition. Am J Obstet Gynecol 2007; 196:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/48\">",
"      Novy MJ, Walsh SW. Dexamethasone and estradiol treatment in pregnant rhesus macaques: effects on gestational length, maternal plasma hormones, and fetal growth. Am J Obstet Gynecol 1983; 145:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/49\">",
"      Garfield RE, Kannan MS, Daniel EE. Gap junction formation in myometrium: control by estrogens, progesterone, and prostaglandins. Am J Physiol 1980; 238:C81.",
"     </a>",
"    </li>",
"    <li>",
"     Fuchs, AR. The role of oxytocin in parturition. In: The Physiology and Biochemistry of the Uterus in Pregnancy and Labour, Huszar, G, (Ed), CRC Press, Boca Raton, Florida 1986. p. 163.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/51\">",
"      Germain, AM, Kato, S, Villarroel, LA, Valenzuela, GJ, Ser&oacute;n-Ferr&eacute;, M. Human term and preterm delivery is preceded by a rise in maternal plasma 17*-estradiol. Prenat Neonat Med 1996; 1:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/52\">",
"      Figueroa JP, Honnebier MB, Binienda Z, et al. Effect of a 48-hour intravenous delta 4-androstenedione infusion on the pregnant rhesus monkey in the last third of gestation: changes in maternal plasma estradiol concentrations and myometrial contractility. Am J Obstet Gynecol 1989; 161:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/53\">",
"      Giussani DA, Jenkins SL, Mecenas CA, et al. Daily and hourly temporal association between delta4-androstenedione-induced preterm myometrial contractions and maternal plasma estradiol and oxytocin concentrations in the 0.8 gestation rhesus monkey. Am J Obstet Gynecol 1996; 174:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/54\">",
"      Mecenas CA, Giussani DA, Owiny JR, et al. Production of premature delivery in pregnant rhesus monkeys by androstenedione infusion. Nat Med 1996; 2:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/55\">",
"      Zeeman GG, Khan-Dawood FS, Dawood MY. Oxytocin and its receptor in pregnancy and parturition: current concepts and clinical implications. Obstet Gynecol 1997; 89:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/56\">",
"      Fuchs AR, Fuchs F. Endocrinology of human parturition: a review. Br J Obstet Gynaecol 1984; 91:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/57\">",
"      Nathanielsz PW, Honnebier MB, Mecenas C, et al. Effect of the oxytocin antagonist atosiban (1-deamino-2-D-tyr(OET)-4-thr-8-orn-vasotocin/oxytocin) on nocturanl myometrial contractions, maternal cardiovascular function, transplacental passage, and fetal oxygenation in the pregnant baboon during the last third of gestation. Biol Reprod 1997; 57:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/58\">",
"      Fuchs AR, Fuchs F, Husslein P, et al. Oxytocin receptors and human parturition: a dual role for oxytocin in the initiation of labor. Science 1982; 215:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/59\">",
"      Fuchs AR, Fuchs F, Husslein P, Soloff MS. Oxytocin receptors in the human uterus during pregnancy and parturition. Am J Obstet Gynecol 1984; 150:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/60\">",
"      Dawood MY, Wang CF, Gupta R, Fuchs F. Fetal contribution to oxytocin in human labor. Obstet Gynecol 1978; 52:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/61\">",
"      Ferguson, JKW. A study of the motility of the intact uterus at term. Surg Gynecol Obstet 1941; 73:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/62\">",
"      Campbell EA, Linton EA, Wolfe CD, et al. Plasma corticotropin-releasing hormone concentrations during pregnancy and parturition. J Clin Endocrinol Metab 1987; 64:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/63\">",
"      Sasaki A, Shinkawa O, Margioris AN, et al. Immunoreactive corticotropin-releasing hormone in human plasma during pregnancy, labor, and delivery. J Clin Endocrinol Metab 1987; 64:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/64\">",
"      Robinson BG, Emanuel RL, Frim DM, Majzoub JA. Glucocorticoid stimulates expression of corticotropin-releasing hormone gene in human placenta. Proc Natl Acad Sci U S A 1988; 85:5244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/65\">",
"      Potter E, Behan DP, Fischer WH, et al. Cloning and characterization of the cDNAs for human and rat corticotropin releasing factor-binding proteins. Nature 1991; 349:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/66\">",
"      Petraglia F, Benedetto C, Florio P, et al. Effect of corticotropin-releasing factor-binding protein on prostaglandin release from cultured maternal decidua and on contractile activity of human myometrium in vitro. J Clin Endocrinol Metab 1995; 80:3073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/67\">",
"      McLean M, Bisits A, Davies J, et al. A placental clock controlling the length of human pregnancy. Nat Med 1995; 1:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/68\">",
"      Challis JR, Matthews SG, Van Meir C, Ramirez MM. Current topic: the placental corticotrophin-releasing hormone-adrenocorticotrophin axis. Placenta 1995; 16:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/69\">",
"      Clifton VL, Read MA, Leitch IM, et al. Corticotropin-releasing hormone-induced vasodilatation in the human fetal-placental circulation: involvement of the nitric oxide-cyclic guanosine 3',5'-monophosphate-mediated pathway. J Clin Endocrinol Metab 1995; 80:2888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/70\">",
"      Chakravorty A, Mesiano S, Jaffe RB. Corticotropin-releasing hormone stimulates P450 17alpha-hydroxylase/17,20-lyase in human fetal adrenal cells via protein kinase C. J Clin Endocrinol Metab 1999; 84:3732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/71\">",
"      Smith R, Mesiano S, Chan EC, et al. Corticotropin-releasing hormone directly and preferentially stimulates dehydroepiandrosterone sulfate secretion by human fetal adrenal cortical cells. J Clin Endocrinol Metab 1998; 83:2916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/72\">",
"      Aggelidou E, Hillhouse EW, Grammatopoulos DK. Up-regulation of nitric oxide synthase and modulation of the guanylate cyclase activity by corticotropin-releasing hormone but not urocortin II or urocortin III in cultured human pregnant myometrial cells. Proc Natl Acad Sci U S A 2002; 99:3300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/73\">",
"      Wadhwa PD, Garite TJ, Porto M, et al. Placental corticotropin-releasing hormone (CRH), spontaneous preterm birth, and fetal growth restriction: a prospective investigation. Am J Obstet Gynecol 2004; 191:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/74\">",
"      Potestio FA, Zakar T, Olson DM. Glucocorticoids stimulate prostaglandin synthesis in human amnion cells by a receptor-mediated mechanism. J Clin Endocrinol Metab 1988; 67:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/75\">",
"      Marinoni E, Korebrits C, Di Iorio R, et al. Effect of betamethasone in vivo on placental corticotropin-releasing hormone in human pregnancy. Am J Obstet Gynecol 1998; 178:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/76\">",
"      Korebrits C, Yu DH, Ramirez MM, et al. Antenatal glucocorticoid administration increases corticotrophin-releasing hormone in maternal plasma. Br J Obstet Gynaecol 1998; 105:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/77\">",
"      Wadhwa PD, Porto M, Garite TJ, et al. Maternal corticotropin-releasing hormone levels in the early third trimester predict length of gestation in human pregnancy. Am J Obstet Gynecol 1998; 179:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/78\">",
"      Pitera AE, Smith GC, Wentworth RA, Nathanielsz PW. Parathyroid hormone-related peptide (1 to 34) inhibits in vitro oxytocin-stimulated activity of pregnant baboon myometrium. Am J Obstet Gynecol 1998; 179:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/79\">",
"      Ambrus G, Rao CV. Novel regulation of pregnant human myometrial smooth muscle cell gap junctions by human chorionic gonadotropin. Endocrinology 1994; 135:2772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/80\">",
"      MacLennan AH, Nicolson R, Green RC. Serum relaxin in pregnancy. Lancet 1986; 2:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/81\">",
"      Bell RJ, Permezel M, MacLennan A, et al. A randomized, double-blind, placebo-controlled trial of the safety of vaginal recombinant human relaxin for cervical ripening. Obstet Gynecol 1993; 82:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/82\">",
"      Romero R, Avila C, Brekus CA, Morotti R. The role of systemic and intrauterine infection in preterm parturition. Ann N Y Acad Sci 1991; 622:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/83\">",
"      Osmers RG, Bl&auml;ser J, Kuhn W, Tschesche H. Interleukin-8 synthesis and the onset of labor. Obstet Gynecol 1995; 86:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/84\">",
"      Dudley DJ. Pre-term labor: an intra-uterine inflammatory response syndrome? J Reprod Immunol 1997; 36:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/85\">",
"      Kelly RW. Inflammatory mediators and parturition. Rev Reprod 1996; 1:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/86\">",
"      Unal ER, Cierny JT, Roedner C, et al. Maternal inflammation in spontaneous term labor. Am J Obstet Gynecol 2011; 204:223.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/87\">",
"      Norwitz ER, L&oacute;pez Bernal A, Starkey PM. Tumor necrosis factor-alpha selectively stimulates prostaglandin F2 alpha production by macrophages in human term decidua. Am J Obstet Gynecol 1992; 167:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/0/6153/abstract/88\">",
"      Mendelson CR. Minireview: fetal-maternal hormonal signaling in pregnancy and labor. Mol Endocrinol 2009; 23:947.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6758 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-AB2AAAC1E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_0_6153=[""].join("\n");
var outline_f6_0_6153=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LABOR AT TERM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHYSIOLOGICAL PHASES OF MYOMETRIAL ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Phase 0: inhibitors active",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Phase 1: myometrial activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Phase 2: stimulatory phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Phase 3: involution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Parturition cascade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      THE ROLE OF THE FETUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MYOMETRIAL ACTIVATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HORMONES INVOLVED IN THE PARTURITIONAL CASCADE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prostaglandins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Progesterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Estrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Oxytocin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hypothalamic-pituitary-adrenal factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Corticotropin releasing hormone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Parathyroid hormone-related peptide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Luteinizing hormone/human chorionic gonadotropin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Relaxin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Cytokines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=related_link\">",
"      Cervical insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=related_link\">",
"      Pathogenesis of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11994?source=related_link\">",
"      Prevention of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=related_link\">",
"      Principles of labor induction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_0_6154="Pulsus paradoxus mechanism";
var content_f6_0_6154=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    Measurement and mechanism of pulsus paradoxus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 687px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Doppler echocardiogram in a patient with cardiac tamponade. Note the inspiratory increase of tricuspid flow velocities (A) and the expiratory increase of mitral (B) and aortic (C) flow velocities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Hoit BD. Imaging the pericardium. Cardiol Clin 1990; 8:594. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_0_6154=[""].join("\n");
var outline_f6_0_6154=null;
var title_f6_0_6155="Standard PD solution";
var content_f6_0_6155=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Standard peritoneal dialysis solution",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Volume (liters)",
"       </td>",
"       <td>",
"        0.25, 0.5, 1.0, 1.5, 2.5, 3.0, 5.0, 6.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium (mEq/L)",
"       </td>",
"       <td>",
"        132",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potassium (mEq/L)",
"       </td>",
"       <td>",
"        0-2, mostly 0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucose (g/dL)",
"       </td>",
"       <td>",
"        1.5, 2.5, 4.0, 25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium (mEq/L)",
"       </td>",
"       <td>",
"        2.5-3.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Magnesium (mEq/L)",
"       </td>",
"       <td>",
"        0.5-1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactate (mEq/L)",
"       </td>",
"       <td>",
"        35-40",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dinesh Chatoth, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_0_6155=[""].join("\n");
var outline_f6_0_6155=null;
var title_f6_0_6156="Causes of acquired goiter in children";
var content_f6_0_6156=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F77604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F77604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of acquired goiter in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Inflammatory causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chronic autoimmune (Hashimoto's) thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Subacute granulomatous thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acute suppurative thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colloid goiter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iodine-deficiency goiter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Ingestion of goitrogens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Iodine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lithium carbonate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Foodstuffs (cassava, millet)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Thyroid infiltrative disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Histiocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cystinosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Toxic goiter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Graves' disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Autonomously functioning thyroid adenoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Activating mutations of the TSH receptor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Activating mutations of the G protein alpha subunit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Thyroid cysts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Thyroglossal duct cysts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid adenomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Thyroid carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Papillary carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Follicular carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Medullary carcinoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_0_6156=[""].join("\n");
var outline_f6_0_6156=null;
var title_f6_0_6157="Spinal cord disorders";
var content_f6_0_6157=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F50336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F50336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Important causes of spinal cord dysfunction*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Course",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical spondylotic myelopathy",
"       </td>",
"       <td>",
"        Usually &gt;60 years",
"       </td>",
"       <td>",
"        Progressive or stepwise course",
"       </td>",
"       <td>",
"        Moderate-severe cases demonstrate gait and leg spasticity and amyotrophy of hand or arms",
"       </td>",
"       <td>",
"        MRI cervical spine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transverse myelitis",
"       </td>",
"       <td>",
"        Children, young adults",
"       </td>",
"       <td>",
"        Subacute",
"       </td>",
"       <td>",
"        Segmental cord syndrome",
"       </td>",
"       <td>",
"        MRI and CSF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viral myelitis",
"       </td>",
"       <td>",
"        Any age",
"       </td>",
"       <td>",
"        Acute-subacute",
"       </td>",
"       <td>",
"        Pure motor syndrome or Segmental cord syndrome",
"       </td>",
"       <td>",
"        MRI and CSF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epidural abscess",
"       </td>",
"       <td>",
"        Any age",
"       </td>",
"       <td>",
"        Subacute; may worsen abruptly",
"       </td>",
"       <td>",
"        Segmental cord syndrome",
"       </td>",
"       <td>",
"        MRI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infarction",
"       </td>",
"       <td>",
"        Usually &gt;60 years",
"       </td>",
"       <td>",
"        Abrupt onset",
"       </td>",
"       <td>",
"        Anterior cord syndrome",
"       </td>",
"       <td>",
"        MRI with diffusion weighted sequences",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vascular malformation",
"       </td>",
"       <td>",
"        <p>",
"         &gt;40 years (dural fistula)",
"        </p>",
"        <p>",
"         20's (intramedullary AVM)",
"        </p>",
"       </td>",
"       <td>",
"        Acute and/or stepwise",
"       </td>",
"       <td>",
"        Radicuomyelopathy",
"       </td>",
"       <td>",
"        MRI, spinal angiography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subacute combined degeneration",
"       </td>",
"       <td>",
"        Any age",
"       </td>",
"       <td>",
"        Slowly progressive",
"       </td>",
"       <td>",
"        Dorsal cord syndrome",
"       </td>",
"       <td>",
"        Vitamin B12 levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiation",
"       </td>",
"       <td>",
"        Any age",
"       </td>",
"       <td>",
"        Slowly progressive; beginning 6-12 months after radiation therapy",
"       </td>",
"       <td>",
"        Segmental cord syndrome or Ventral cord syndrome",
"       </td>",
"       <td>",
"        MRI, clinical history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syringomyelia",
"       </td>",
"       <td>",
"        Children, young adults",
"       </td>",
"       <td>",
"        Slowly progressive",
"       </td>",
"       <td>",
"        Central cord syndrome",
"       </td>",
"       <td>",
"        MRI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epidural metastasis",
"       </td>",
"       <td>",
"        Usually &gt;50 years",
"       </td>",
"       <td>",
"        Subacute, may worsen abruptly",
"       </td>",
"       <td>",
"        Segmental cord syndrome",
"       </td>",
"       <td>",
"        MRI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intramedullary tumor",
"       </td>",
"       <td>",
"        Young adults",
"       </td>",
"       <td>",
"        Slowly progressive",
"       </td>",
"       <td>",
"        Central cord syndrome",
"       </td>",
"       <td>",
"        MRI with gadolinium enhancement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ALS",
"       </td>",
"       <td>",
"        Usually &gt;60 years",
"       </td>",
"       <td>",
"        Slowly progressive",
"       </td>",
"       <td>",
"        Pure motor syndrome",
"       </td>",
"       <td>",
"        Electromyography",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MRI: magnetic resonance imaging; CSF: cerebrospinal fluid; AVM: arteriovenous malformation; ALS: amyotrophic lateral sclerosis.",
"     <br>",
"      * This is a partial list of causes. Please see topic \"Disorders affecting the spinal cord\" for a more complete differential diagnosis.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_0_6157=[""].join("\n");
var outline_f6_0_6157=null;
var title_f6_0_6158="Average annual fracture rate";
var content_f6_0_6158=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F58577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F58577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Annual fracture rate in men and women",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 300px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Average annual fracture incidence rate per 10,000 men and women in Leicester, United Kingdom. The rate begins to increase in women after age 44 years as they enter menopause and in men after age 74 years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Donaldson LJ, Cook A, Thomson RG. Incidence of fractures in a geographically defined population.&nbsp;J Epidemiol Community Health 1990; 44:241.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_0_6158=[""].join("\n");
var outline_f6_0_6158=null;
var title_f6_0_6159="Complete rectal prolapse";
var content_f6_0_6159=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Complete rectal prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 299px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The everted rectal wall appears as a tubular mass made up of several concentric mucosal folds.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Nelson, H, Dozois, R. Prolapse of the rectum. In: Sabiston Review of Surgery, 3rd ed, Townsend, CM, Sabiston, DC, WB Saunders, Philadelphia, 2001. p.978. Copyright &copy; 2001 Mayo Foundation for Medical Education and Research",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_0_6159=[""].join("\n");
var outline_f6_0_6159=null;
